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Abstract

Histone post-translational modification dysregulation contributes to
toxicity in Amyotrophic Lateral Sclerosis proteinopathy models

By: Seth Bennett

Advisor: Prof. Mariana Torrente
Amyotrophic Lateral Sclerosis (ALS) is the third most common adult onset
neurodegenerative disorder worldwide. It is generally characterized by progressive
paralysis starting at the limbs ultimately leading to death caused by respiratory failure.
There is no cure and current treatments fail to slow the progression of the disease. As
such, new treatment options are desperately needed. Epigenetic targets are an
attractive possibility because they are reversible.
Chapter 1 presents an introduction to ALS and epigenetics. Epigenetics refers to
heritable changes in gene expression unrelated to changes in DNA sequence. Three
main epigenetic mechanisms include the methylation of DNA, micro-RNAs and the posttranslational modification of histone proteins. Histone modifications occur in many
amino acid residues and include phosphorylation, acetylation, methylation as well as
other chemical moieties. Recent evidence points to a possible role for epigenetic
mechanisms in the etiology of ALS. Here we review recent advances linking ALS and
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epigenetics, with a strong focus on histone modifications. Both local and global changes
in histone modification profiles are associated with ALS drawing attention to potential
targets for future diagnostic and treatment approaches.
Chapter 2 presents a survey of the histone PTM landscape in the FUS and TDP43 proteinopathy overexpression yeast models. A prominent feature of ALS is the
accumulation of protein inclusions in the cytoplasm of degenerating neurons; however,
the particular protein comprising these inclusions varies. The RNA-binding proteins
TDP-43 and FUS are most notable in ALS. Here, we comprehensively delineate histone
PTM profiles in ALS yeast proteinopathy models. Remarkably, we find distinct changes
in histone modification profiles for each. We detect the most striking changes in the
context of FUS aggregation: changes in several histone marks support a global
decrease in gene transcription.
Chapter 3 presents how treating FUS yeast with trichostatin A suppresses growth
suppression. The FUS protein aggregates and forms inclusions within affected neurons.
However, the precise mechanisms connecting protein aggregation to neurotoxicity
remain under intense investigation. Recent evidence points to the contribution from
epigenetics to ALS. Here, we describe the first report of amelioration of disease
phenotypes by controlling histone acetylation on specific modification sites. We show
that inhibiting histone deacetylases (HDACs), via treatment with TSA, suppresses the
toxicity associated with FUS overexpression in yeast by preserving the levels of
H3K56ac and H3K14ac without affecting FUS expression or its aggregation. Our data
raises the novel hypothesis that the toxic effect of protein aggregation in
neurodegeneration is related to its association with altered histone marks.
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Chapter 4 presents our model of how FUS is dysregulating PTMs and
contributing to toxicity in the yeast overexpression model. We interrogated the binding
partners of FUS by co-immunoprecipitation assays followed by identification by mass
spectrometry. We identified that Nop1, a histone methyltransferase involved in rRNA
biogenesis, is a binding partner of FUS. We then measured the levels and localization
of the histone modifying enzymes Ipl1, Gcn5 and Rtt109 which are responsible for the
deposition of H3S10ph, H3K14ac and H3K56ac, respectively. We did observe a change
in the levels of these enzymes, but found that Ipl1 and Rtt109 are significantly excluded
for the nucleus, while the former colocalizes with FUS. We also found that FUS-RNA
binding is not necessary for histone PTM dysregulation. We propose that exclusion of
Ipl1 from the nucleus is driving the dysregulation of histone PTMs and that reduced
levels of H3K56ac and FUS-Nop1 binding are causing reduced total RNA levels, likely
representing decreased rRNA which contributing to FUS overexpression toxicity.
Chapter 5 presents the role H3S10ph in the pathology of C9orf72 ALS and
identifies Ipl1/Aurora B Kinase as a possible therapeutic target. The most common
genetic cause of ALS is an accumulation of hexanucleotide repeat expansions (HREs)
in the C9orf72 gene. HREs in C9orf72 lead to the production of dipeptide repeat
proteins (DPRs), including proline-arginine (PR). DPRs and PR have linked to a number
of cellular deficits, but how DPRs influence the epigenome is still poorly understood.
Here, we show that overexpression of PR50 in yeast is associated with significantly
increased phosphorylation levels H3S10ph. Remarkably, induced pluripotent stem cells
and fibroblasts derived from C9orf72 ALS patients display significant increases in the
levels of H3S10ph. We also find Aurora B Kinase, the human homologue of Ipl1, to be
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enriched in nucleus in C9orf72. Furthermore, we show that knockdown of Ipl1, Aurora B
kinase yeast homolog, abates H3S10ph to control levels and rescues growth
suppression elicited by PR50. Overall, we show that the DPR PR is connected to
increased levels of H3S10ph, and identify Aurora B Kinase as a possible therapeutic
target in the treatment of ALS.
Our results highlight a great need for the inclusion of epigenetic mechanisms in
the study of neurodegeneration. We hope our work will pave the way for discovery of
more effective therapies to treat patients suffering from ALS and other
neurodegenerative diseases.
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Chapter 1: Introduction1,a
1.1 Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease
characterized by the selective loss of both upper and lower motor neurons.2 As motor
neurons in the spinal cord, brain, and brainstem weaken, skeletal muscular atrophy
spreads through the patient.3 Depending on the type of motor neurons affected, ALS
can present itself clinically as either limb onset-manifesting as muscle weakness- or
bulbar onset manifesting as speech impediments.2 Prognosis is poor and quality of life
is significantly reduced as most patients succumb to the disease within three years of
diagnosis.4 There is no cure for ALS and the only two FDA approved drugs, RilutekÒ
(riluzole) and RadicavaÒ (edaravone), fail to stop progression of the disease.5-7
ALS is classified into two categories: familial and sporadic. Familial ALS
represents about 10% of all cases, where the disease can be attributed to a particular
gene mutation running in families.8 Sporadic cases, on the other hand, represent the
remaining 90% for which there is no family history of the disease. Numerous genes
have been associated to ALS.9 Some of these include superoxide dismutase 1 (SOD1),
chromosome 9 open reading frame 72 (C9orf72), Fused in Sarcoma (FUS), and TAR
DNA binding protein 43 (TDP-43).10 Both familial and sporadic cases share similar
pathology; the overwhelming majority of cases present neuronal TDP-43 protein
aggregates.11 Interestingly, not only neuronal cells are affected by these mutations. Glial
cells harboring SOD1 mutations have been shown to drive motor neuron degeneration
a
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in experimental models.12-15 More specifically, microglia bearing a SOD1 mutation
caused motor neuron degeneration in otherwise healthy mice,16 and human derived
motor neurons co-cultured with these microglia showed signs of motor degeneration as
well.17 Nevertheless, the true origin of ALS remains obscure. Therefore, there is an
urgent need to understand the pathogenesis of ALS in order to develop new treatment
options. Aberrant epigenetic mechanisms linked to ALS are beginning to be discovered.
These are attractive therapeutic targets as they are pharmaceutically accessible and
largely reversible.18
1.2 Epigenetics
Epigenetics refers to heritable alterations in gene expression without modification
to the genome.19 Three main epigenetic mechanisms include DNA methylation, micro
RNAs (miRNA), and histone post-translational modifications (PTMs).
1.2.1 DNA methylation
DNA methylation takes place on the 5’ carbon on cytosine bases and is involved
in transcription regulation.20 DNA methylation at enhancers is key in determining cell
line fate.21 Hypermethylation at gene promoters is generally found to silence gene
expression, while methylation in the coding region can increase transcription. DNA
methylation is a crucial rate-controlling step that occurs in genomic regulatory regions
during transcription, making it detectable and possibly even reversible for treatment
purposes.22
1.2.2 micro RNA
miRNAs are key regulators of gene expression.23 miRNAs are non-coding short
pieces of RNA, containing approximately 22 nucleotides, that generally bind to the 3’-
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untranslated region (3’-UTR) of mRNA, causing degradation of the mRNA and
translational silencing.
1.2.2 Histone post-translational modifications
Histones are proteins which package and organize cellular DNA.24 146 bases of
DNA coil around two H2A/H2B dimers and one H3/H4 tetramer. The histone N-terminal
tails are heavily modified with a multitude of chemical moieties, including mono-, di- and
tri-methylation, acetylation, phosphorylation, SUMOylation and ubiquitination occurring
in a variety of residues.25 Histone post-translational modifications (PTMs) play an
important role in gene regulation by controlling the accessibility of DNA to the
transcriptional machinery. Initially, histone PTMs were thought to only impact gene
transcription by controlling how tightly DNA wraps around the histones. For example,
histone acetylation on lysine residues lowers the positive charge on histones and the
strength of interaction with the negatively charged DNA backbone favoring gene
transcription. Conversely, hypoacetylation is associated with transcriptional silencing.2629

More recently, it has been established that these modifications actually comprise a

“histone code” that other proteins can ‘write,’ ‘erase’ and ‘read.’30, 31 Histone PTMs can
also affect one another through ‘cross talk.’32 For example, the phosphorylation of
Serine 10 on Histone H3 (H3S10ph) promotes acetylation on Lysine 16 on Histone H4
(H4K16ac) and also inhibits tri-methylation on Lysine 9 on Histone H3 (H3K9me3).33, 34
1.3 Epigenetic contributions to ALS
While a thorough understanding of the underlying mechanisms resulting in ALS
have yet to be reached, recent evidence shows that alterations in the epigenetic
landscape might contribute to disease pathology. Here, we review recent evidence
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showing a link between ALS and epigenetics. While we incorporate exciting findings
featuring DNA methylation and miRNA mechanisms, we mostly focus on recent
advances linking histone PTMs to ALS.
1.3.1 DNA methylation in ALS
DNA methylation on cytosine bases is one the most studied epigenetic factors in
neurodegenerative diseases and ALS.18 In post-mortem spinal tissue from sporadic ALS
patients, there are global alterations in DNA methylation and hydroxymethylation.35 Not
surprisingly, many of the genes that were hypo- or hypermethylated showed
corresponding changes in decreasing or increasing gene expression. Interestingly,
these genes were largely involved with the immune and inflammatory responses. Other
reports link Dnmt3a, a de novo DNA methyltransferase, to ALS phenotypes.21, 36-38 Mice
lacking Dnmt3a are hypoactive, underperformed on tests of neuromuscular function and
motor coordination and had decreased numbers of motor neurons akin to SOD1 mouse
models of ALS.36 Interestingly, Dnmt3a is required for the development of motor
neurons in vitro.21 Moreover, apoptosis observed in NSC34 cells treated with
camptothecin and in wild-type mice with unilateral nerve avulsion was driven by
increased activity of Dnmt3a, Dnmt1 – a maintenance DNA mehtyltranserfase – and
increased levels of 5-methyltransferase.37 Remarkably, Dnmt inhibition with RG108, a
DNA methyltransferase inhibitor, blocked apoptosis in both cultured neurons and mice.
In agreement, levels of Dnmt1, Dnmt3a and 5-methylcytosine are upregulated in the
brain and spinal cords of ALS patients.37 Furthermore, Dnmt3a was found in the
mitochondria of the CNS and skeletal muscle of adult wild-type mice, but was
significantly reduced in the mitochondria of ALS SOD1 mice.38 Counter intuitively, there
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was also an increase in mitochondrial DNA methylation in the SOD1 mice, including at
the 16S ribosomal RNA gene, which encodes for the mitochondrial 16 S rRNA subunit.
The SOD1 mice also displayed increased mitophagy- the degradation of the
mitochondria by way of autophagy- which contributed to neuronal degeneration.
Recently, genome-wide association studies discovered differentially methylated
genes involved in pathways important to ALS and frontotemporal dementia(FTD)-ALS.39
In the FTD-ALS subgroup, pathway analysis revealed three gene sets displaying
enriched DNA methylation; among these is the Meissner Brain HCP with H3K4me3 and
H3K27me3 gene set. This gene set contains genes with high-CpG-density promoters
(HCP) bearing the bivalent histone H3 trimethylation mark at K4 and K27 (H3K4me3
and H3K27me3),40 suggesting that both DNA methylation and histone PTMs are
important in the progression of FTD-ALS. Interestingly, H3K4me3 and H3K27me3 are
associated with neurological function.41 For an in-depth examination of the links
between DNA methylation and ALS, we direct the reader to a thorough review by Martin
& Wong.42
1.3.2 miRNA and ALS
miRNAs are an epigenetic mechanism that reduce gene expression by binding
Argonaute 2 and forming the RNA-induced silencing complex (RISC).43, 44 The complex
then binds the 3’-UTR of a specific mRNA, and degrades it if there is an extensive
match between the mRNA and miRNA or, if there is a less extensive match, just binds
the mRNA repressing expression of the bound transcript.45-47 miRNAs are associated
with neurodegenerative diseases such as Alzheimer’s Disease,48 Parkinson’s
Disease,49 and Huntington’s Disease.50 Several lines of evidence link ALS to miRNA
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dysregulation.18, 51 For instance, there is a global decrease in miRNA levels in the spinal
cords of ALS patients.52 The levels of miRNAs were compared to healthy controls and
90 miRNAs were found to be dysregulated. These miRNAs had mRNA targets involved
in cell death, immune response and brain development that may possibly contribute to
ALS etiology. Some of these included upregulation of miR-155 and miR-142. These
miRNA target ubiquilin 2 (UBQLN2), the RNA binding protein Fox-1 (RBFOX1) and
reelin (RELN), a protein secreted by certain neurons to guide neuronal migration.53 All
of these genes have been associated with neurodegeneration.52 Interestingly, genes
involved with immune response were also found to be dysregulated in sALS patients
with aberrant DNA methylation patterns.35 This suggests a role for epigenetics
contributing to cellular demise caused by inflammation in ALS. Furthermore, TDP-43
overexpression in AinV15 mouse embryonic stem cells inhibited the endogenous
activity of miRNAs regulating the genes EIF2C4/AGO4.52 These genes are members of
the RNA-induced silencing complex- the ribonucleoprotein complex that is responsible
for translational silencing by cleaving miRNA and complementary mRNAs- and have
been found to be dysregulated in ALS.54, 55 Moreover, a large number of miRNAs were
differentially expressed in the spinal cord motor neurons of sporadic ALS patients.56
Functional analysis revealed the some of the upregulated miRNAs could bind to the 3’UTR of low molecular weight neurofilament (NFL),56 an important cytoskeleton protein
involved in mitochondrial transport in motor neurons,57 leading to a decrease in NFL
mRNA levels. Interestingly, protein levels of NFL are found to lowered in ALS.58-60
Additionally, FUS disrupts the circuitry between miR-409 and miR-495 in motor neurons
derived from embryonic mouse cells with a FUS knock-in mutation.61 miR-409 and miR-
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495 regulate the expression of Gria2, which encodes for a subunit of a-amino-3hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor. The upregulation of
these miRNAs led to a decrease in Gria2 mRNA. The authors validated that miR-409
and miR-495 bind the 3’-UTR of Gria2. Furthermore, FUS stabilizes the interactions
between the miRNA and their target, leading to decreased Gria2 expression.61 Gria2
alteration has been previously implicated in motor neuron degeneration via alterations in
Ca2+ homeostasis leading to excitotoxicity.62-64
In light of all these alterations, miRNA profiling has been proposed as a potential
biomarker panel for neurodegeneration and ALS (Table 1).51 For example, microarray
analysis of leukocytes from sporadic ALS patients compared with healthy controls
revealed a eight miRNAs that were dysregulated.65 Of these miRNA, only miR-338-3p
was upregulated, and interestingly it has been previously found to be dysregulated in
the brains of ALS patients.66 A study of skeletal tissue from SOD1 G93A mice revealed
that miR-206 was upregulated, and confirmed to also be upregulated in the plasma of
ALS patients.67 Similarly, comparison of circulating miRNAs in plasma form sporadic
ALS patients and healthy controls revealed nine dysregulated miRNAs, three of which
were upregulated.68 Two of these miRNAs, has-miR-46469-5p and has-miR4299, were
confirmed to be respectively up- and down-regulated in a larger ALS patient cohort.
Interestingly, both of these miRNAs target EPHA4, a gene that is has been associated
with ALS in animal models.69 EPHA4 contributes to brain development and neuronal
migration, much like RELN discussed above.52 These results suggest epigenetic
mechanisms may be contributing to ALS pathology through alterations in development.
Furthermore, a number of miRNAs have been found to be dysregulated in the
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leukocytes of ALS patients.70 Specifically, AAKT, which encodes for miR-338, is upregulated, while DNM2, which encodes for miR-638, is down-regulated. Both of these
miRNAs have been found to be involved in other neurodegenerative diseases, such as
FTD and hereditary spastic paraplegia.71, 72 Overall, miRNAs appear to play an
important role in the pathology of ALS and show promise as robust diagnostic
biomarkers.
1.3.3 Histone modifications and chromatin remodeling enzymes in ALS
Compared to other diseases, the study of epigenetic mechanisms involved in
ALS is just in its beginning stages and relatively few studies examining the association
between epigenetics and the disease have been carried out. While most investigations
have focused in DNA methylation, recent evidence has linked aberrant changes in
histone PTMs levels to neurodegenerative disease and ALS.8, 18, 73
Remarkably, many enzymes responsible for installing or removing histone
modifications have also been associated with ALS (Table 2). For instance, histone
acetyltransferases (HATs) and histone deacetylases (HDACs) are responsible for the
addition and removal of acetyl groups on histones, respectively. There are two classes
of HDACs that are Zn2+ dependent including HDACs 1-11. A third class, Sirtuins (SIRT)
1-7, are NAD+ dependent.74 HDACs are drug targets for the treatment of many
diseases, including cancer, inflammatory disease and pulmonary disease.75-77
Correspondingly, there are a variety of kinases responsible for phosphorylating
histones, including Aurora B kinase and AMP kinase.78 Lastly, many histone
methyltransferases are responsible for the deposition and removal of methyl groups on
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lysine and arginine residues on histones.79 These enzymes can be specific to mono-, diand tri-methylation, as well as symmetric and asymmetric methylation.80
1.3.3.1 Histone acetylation, HATs and HDACs
Histone acetylation has been repeatedly associated with ALS. In a FUS
overexpression model in HeLa cells, FUS binds to and inhibits CBP/p300 HAT at a
specific gene promoter and causes hypoacetylation near the CCND1 gene.81 This
causes reduced expression of CCND1, which encodes for cyclin D1, a protein required
for progression through the cell cycle.82 HeLa cell models have been repeatedly used in
ALS research.83-85 Evidencing another link between histone acetylation and ALS, ELP3
– a protein with HAT activity- was linked to motor neuron degeneration in ALS in a
microsatellite-based genetic association study.86 In zebra fish embryos, ELP3 knock
down with anti-sense RNA leads to motor neuron degeneration in a dose dependent
manner.86 ELP3 acetylates Lysine 14 on Histone H3 (H3K14) and Lysine 8 on Histone
H4 (H4K8).87 Interestingly, mutagenesis screening in Drosophila revealed that ELP3 is
critical for neuronal communication and survival.86 These results support a role for
histone hypoacetylation in ALS pathology. In fact, ELP3 directly regulates heat shock
protein 70 (HSP70) expression by acetylation of histones H3 and H4 in yeast;88 hence,
ELP3 defects could result in motor neuron degeneration through a decrease in the
transcription of HSP70.82
Recently, we characterized global histone acetylation levels in yeast ALS
proteinopathy models.73 Many cellular pathways are conserved from yeast to humans.89,
90

Furthermore, yeast recapitulate the cellular toxicity and cytoplasmic foci of TDP-43

and FUS seen in human pathology.91, 92 In fact, yeast models have enabled
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identification of common ALS genetic risk factors.93 Yeast overexpressing human FUS
showed significantly decreased levels of acetylation on Lysine 14 and Lysine 56 on
Histone H3 (H3K14 and H3K56).73 These histone PTM are conserved in humans.
H3K14ac and H3K56ac are both involved in the DNA damage checkpoint activation.94-96
Furthermore, H3K14ac is also found at the promoter of actively transcribed genes.97
Interestingly, yeast overexpressing FUS had overall decreased RNA levels, suggesting
that histone hypoacetylation leads to reduced transcription.73 Surprisingly, an analogous
TDP-43 yeast proteinopathy model did not display the same decreases in histone
acetylation, but instead revealed hyperacetylation on Lysines 12 and 16 on Histone 4
(H4K12 and H4K16). H4K12ac is a modification localized on gene promoters and is
associated with gene activation.98 H4K16ac is a particularly interesting modification
because it is associated with both gene expression and repression.99, 100 Remarkably,
each proteinopathy displayed its own distinct histone modification landscape.
Puzzlingly, while both of these models share protein aggregation and cytotoxicity
features, FUS and TDP-43 overexpression resulted in histone hypo- and
hyperacetylation, respectively. This suggests that each proteinopathy and
corresponding histone PTM profile may be leading to ALS in unique ways.
In addition to changes on histone acetylation, HDACs have been thoroughly
implicated in ALS.101 For instance, deletion of Set3- a member of a histone deacetylase
complex, homolog to the human protein ASH1- was found to suppress the toxicity of
TDP-43 inclusions in a yeast model.102 Moreover, post-mortem analysis of brains and
spinal cord tissue derived from ALS patients showed a decrease in HDAC 11 mRNA
and an increase of HDAC 2 mRNA.103 Furthermore, HDAC 1 has been found to
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mislocalize to the cytoplasm in a FUS knock-in mouse model.104 Curiously, posttranslational modification on the histone modifiers themselves appears to be important.
Phosphorylation of serine residues in HDAC1 controls its subcellular localization, and
HDAC1 accumulation in the nucleus was neuroprotective in a mouse model.105 Further
evidence for HDAC perturbations in ALS comes from SOD1 mouse models. SIRT1
levels are decreased in neurons and increased in muscles of mice expressing mutant
SOD1, while SIRT2 mRNA levels decrease in motor neurons in the same model.106 In
NSC34 and HEK293 cells as well as mice expressing wild type and mutant SOD1G93A,
HDAC6 knock-down induced SOD1 aggregation resulting in increased motor neuron
loss.107 In the same mice model, HDAC6 levels drop as ALS symptoms appear and
then plummet as the disease progresses.108 Interestingly, in this mouse model HDAC6
overexpression prolongs life span and delays motor neuron decay by inducing fusion of
autophagosomes to lysosomes and promoting autophagy.108
HDAC cofactors also appear to play a role in disease.109 For example, loss of
NAD+, a SIRT cofactor, contributes to neurodegeneration.110 Furthermore, the loss of
intracellular nicotinamide phosphoribosyltranferase- the rate limiting enzyme in NAD+
synthesis- leads to motor neuron degeneration in mice where the gene was knocked
out.111 Increased activity of PARP1 has been observed to deplete NAD+ pools, and
contributes neurotoxicity.112 Interestingly, silencing of Parp1 is neuroprotective in a
mouse model of cerebellar ataxia,112 and it is a possible therapeutic target for
neurodegeneration.
HDAC inhibition has arisen as a promising therapeutic in various ALS models.
Treatment with trichostatin A, an HDAC inhibitor, ameliorated motor neuron
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degeneration in a SOD1 mouse model.113 In motor neurons derived from ALS patients,
pharmacological inhibition and genetic silencing of HDAC6 reverses axonal transport
defects caused by mutant FUS.114 Furthermore, HDAC inhibition with 4-PB increased
motor function and neuroprotection in transgenic ALS mice.115 Interestingly, treatment
with sodium phenylbutryate, a general HDAC inhibitor, extended survival in SOD1G93A
ALS mouse model,116 and its effect is increased when combined with an antioxidant or
Riluzole.117, 118 Phenylbutyrate has shown to be safe and increase histone acetylation
levels in ALS patients.119 Perplexingly, loss of HDAC function and is related to disease
in some models,113-116 while HDAC inhibition is neuroprotective in others.104, 106-108
Future studies will potentially reconcile these seemingly opposite landscapes and
elucidate their contribution to ALS pathways.
1.3.3.2 Histone methylation and methyltransferases
Lysine and arginine methylation have varying effects on gene expression.
Generally, mono-methylation is associated with transcription activation, while trimethylation is associated with transcription repression.120 Recent evidence has linked
tri-methylation of lysine residues on H3 and H4 with loss-of-function toxicity in ALS
patients with dipeptide repeat expansions (DRE) in C9orf72.121 There is an increase in
H3K9me3, H3K27me3 and H4K20me3 levels around the DREs sequence in brain
tissue from ALS patients compared to healthy controls. These histone PTMs are
strongly associated with gene silencing.120 Decreased levels of C9orf72 mRNA in
patients support a loss-of-function toxicity model.121 Interestingly, treating fibroblasts
derived from patients bearing C9orf72 mutations with a histone demethylating agent
reduced tri-methylation levels near DREs and restored C9orf72 mRNA levels.121

12

In yeast models of ALS, we observed distinct histone methylation profiles for
TDP-43 and FUS proteinopathies.73 Specifically, FUS overexpression is associated with
decreased levels of asymmetric di-methylation on Arginine 3 on Histone H4
(H4R3me2asym), while TDP-43 overexpression is associated with decreased levels of
tri-methylation on Lysine 36 on Histone H3 (H3K36me3). H34Rme2asym is associated
with increased gene expression,122 whereas H3K36me3 is linked to transcriptional
repression by serving as a docking site for HDACs and promoting deacetylation.123, 124
As for acetylation, these results highlight that different proteinopathies can have unique
effects on epigenetic mechanisms. H4Rme2 is linked to H3K14ac,125 which also
decreased in this FUS model, underscoring cross talk between these two modifications.
Protein arginine N-methyltranserfase 1(PRMT1) is a methyltransferase that has
been positively implicated in ALS. PRMT1 is responsible H4R3me2asym, which
promotes histone acetylation and gene transcription.126 In a FUSR521C mouse model of
ALS, overexpression of PRMT1 was found to rescue neurite growth after oxidative
stress.127 The same study showed that PRMT1 activity is inhibited by interaction with
FUS as a stable complex of FUS/PRMT1/Nd1-L mRNA is formed. Nd1-L is an actin
stabilizing protein and is under-expressed in this model. Furthermore, in agreement with
our FUS yeast model results, loss of PRMT1 function -due to FUS mislocalization- led
to the reduction of di-methylation of Arginine 3 on Histone H4 (H4R3me2) causing a
drop in the acetylation of Histone H3 on Lysine 9 and 14, ultimately leading to
transcriptional silencing.128
1.3.3.3 Histone phosphorylation and ubiquitination
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Phosphorylation on serine, threonine and tyrosine histone residues plays an
important role in gene expression, transition through the cell cycle and DNA damage
repair.78 Histone phosphorylation and many enzymes responsible for it have been
implicated in ALS and other neurodegenerative diseases.129 For example, loss of FUS
through RNAi leads to decreased cell proliferation and an increase in H3
phosphorylation in NSC-34 and HEK-293T cells.130 This coincides with altered
expression of genes involved in cell cycle regulation, cytoskeletal organization, oxidative
stress and energy homeostasis, and may point to a loss-of-function mechanism for FUS
mutants related to ALS.
In a FUS overexpression model in yeast, we discovered a reduction in
phosphorylation levels on Threonine 129 on Histone H2B (H2BT129ph).73 In yeast,
reduced H2BT129ph is associated with decreased gene expression.131 In the same
model, we identified a profound decrease in the levels of phosphorylation on Serine 10
on Histone H3 (H3S10ph). H3S10ph is associated with active gene expression.78
Furthermore, H3S10ph promotes acetylation of Histone H3 on Lysine 14 (H3K14ac) in
yeast,132 suggesting histone cross-talk may play an important role in disease processes.
Interestingly, Ilp1, the yeast homologue of human Aurora B kinase, can phosphorylate
both H3S10 and H2BT129. These results suggest Aurora B kinase might be involved in
ALS pathology.
Increased R-Loops (DNA-RNA triple helixes) and DNA double strand breaks
were observed in vitro and in the spinal tissue of ALS patients with mutations in
C9orf72.133 This damage was associated with dipeptide repeats in C9orf72 causing an
accumulation of P62 and impaired H2A ubiquitination at lysine 119 (H2AK119ub1). P62
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is an autophagy protein related to ALS, and its accumulation inhibits RNF168, the
enzyme responsible for ubiquitination on H2A.134 Reduced ubiquitylation impaired ATM
signaling, an important pathway involved in DNA damage repair,135 and perturbed DNA
double strand break repair.133 Figure 1 presents all histone modifications linked to ALS
to date.
One issue that arises whenever discussing histone modification is causality.136
Are histone modifications a consequence of neurodegenerative proteinopathies or do
changes in modifications lead to disease? Further research into how ALS-associated
proteins interact with histone ‘writers’, ‘erasers’ and ‘readers’, and perhaps even the
histone PTMs themselves is necessary to definitively answer this question. This may
still be an emerging field with a number of questions yet to be answered, but as
discussed above for HDACs inhibitors, drugs targeting histone modifiers are effective
treatments in ALS models.113-119 Thus, causality might ultimately be inconsequential, as
pharmaceutical intervention targeting epigenetic features of ALS would alleviate disease
outcomes. A number of histone modifications are associated with ALS, and each
enzyme responsible for adding, removing or reading these modifications is a potential
drugable target. Aside from HATs and HDACs, further research into chemical
modulation of histone kinases, phosphorylases, methyltransferases and demethylases
is needed. For example, inhibitors of protein phosphatase 1 and 2, responsible for
removal of H3S10ph, 137, 138 as well as inhibitors of JMJD6, a Jumonji-domaincontaining protein reported to demethylate H4R3me2139, may be useful therapeutic
targets for ALS.
1.3.3.4 Chromatin remodeling enzymes
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Eukaryotic DNA is packed into chromatin. DNA wraps around histones to form
nucleosomes, the basic units of chromatin. Chromatin structure affects gene expression
by controlling the accessibility to DNA.140 Transcriptionally active chromatin is termed
euchromatin and while transcriptionally silent chromatin is referred to as
heterochromatin.25, 141 Chromatin plays a key role in nearly all eukaryotic DNAtemplated processes such as mitosis, DNA repair, and transcription. Some histone
PTMs directly contribute to chromatin structure. For instance, H4K16ac inhibits the
formation of heterochromatin,142 while H3K9me3 binds Heterochromatin Protein 1
promoting chromatin compaction.34 Additionally, enzymes that target histone PTMs can
also play a role in chromatin compaction. For example, the HDAC SIRT1, which
deacetylates H4K16, also has the ability to dephosphorylate the active site of the
methyltransferase suppressor of variegation 3-9 homologue 1 (SUV39H1), increasing
its activity and consequently increasing H3K27me3 levels and promoting chromatin
compaction.143 Aside from enzymes that directly affect histone PTMs, there a number of
ATP-dependent chromatin remodeling enzymes that move, eject or otherwise
restructure histones to control chromatin structure.144, 145Some of these have been
associated to ALS and neurodegenerative disease. For example, in a TDP-43
overexpression Drosophila model, the chromatin-helicase-DNA binding protein Chd1
was inhibited by TDP-43, which in turn inhibited the stress response needed for
neuronal survival.146 Chd1 alters gene accessibility by modifying chromatin structure.147
This loss of Chd1 function led to decreased expression of protective genes, such as the
proteins involved in the REST and Hsp70 pathway. Correspondingly, up-regulation of
Chd1 was found to be neuroprotective. The human orthologue of Chd1, CHD2,
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physically interacted with TDP-43 and was significantly reduced in the temporal cortex
of patients with ALS.146 Therefore, at least some of toxicity associated with TDP-43
seems to be caused by the reduced expression of protective genes caused by
chromatin rearrangement.
POLR2A, a subunit of the carboxyl-terminal domain of RNA Polymerase II, reads
modifications specifying the recruitment of factors that regulate transcription, mRNA
processing and chromatin remodeling.148 Arginine 1810 of POLR2A is symmetrically dimethylated by protein arginine methyltransferase 5 (PRMT5) and this modification
recruits the Tudor domain of survival of motor neuron (SMN). SMN interacts with
senataxin, which is sometimes mutated in ALS.149 Perturbations in this pathway lead to
the formation of R-loops, genomic instability and pre-mature transcription termination
causing neurodegeneration.148
Furthermore, RNA Polymerase II, as well as TDP-43 and FUS, colocalize with
gH2AX (a histone H2A isoform phosphorylated on serine 139).150 gH2AX is a sign of
DNA double strand breaks.151 gH2AX co-localization with TDP-43 and FUS suggests
these proteins may have a role in double strand break repair. DNA double strand breaks
may be harder to resolve when FUS or TDP-43 mislocalize from the nucleus, promoting
neurodegeneration and suggesting a loss-of-function toxicity model for these two ALSassociated proteins. A summary of the histone and chromatin modifying enzymes
implicated in ALS is presented in Table 2.
Mounting evidence highlights the role of epigenetic mechanisms in ALS
pathology. DNA methylation, miRNAs and histone PTMs have distinct contributions to
neurotoxicity. The evidence reviewed here reveals distinct DNA methylation patterns
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and dysregulation of miRNAs are associated with ALS. Although understudied,
perturbations in the levels of histones modifications lead to alterations of gene
expression and can contribute to the neurodegeneration. Remarkably, these alterations
seem to be distinctly connected to different proteinopathies. Chromatin remodeling
enzymes, which do not specifically impact histone modifications, also contribute to ALS
pathology by reducing expression of survival genes and impairing DNA break repair.
Though exact knowledge of how the different epigenetic mechanisms, in particular
histone PTMs, affect ALS development and progression is still lacking, we are
beginning to characterize them and realizing their potential importance in understanding
ALS. Although much work remains to elucidate causal relationships and mechanisms
linking histone PTMs and neurodegeneration, these findings highlight the critical need
for the inclusion of epigenetics in neurodegenerative disease research. Remarkably,
some of these altered epigenetic profiles can be detected in blood, and may become
useful biomarkers for diagnosis and assessment of disease or treatment progress. We
expect discoveries to come in the next decade will take us beyond establishing the links
between ALS and epigenetics and move towards elucidating the precise epigenetic
mechanisms associated with disease processes and specific symptoms. Pinpointing
how epigenetic changes relate to disease can potentially lead to novel diagnostic and
therapeutic tools for ALS and other neurodegenerative diseases.
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Table 1. List of miRNAs that may act as possible biomarkers for Amyotrophic
Lateral Sclerosis. Adpadted from Bennett et al., Transl Res, 2019.
miRNA

Dysregulation

miR-338-3p

Upregulated

miR-206

Upregulated

has-miR-46469-5p

Upregulated

has-miR-4299

Downregulated

miR-338

Upregulated

miR-638

Downregulated

Tissue

Reference

Leukocytes of
sporadic ALS
patients
Plasma of sporadic
ALS patients
Plasma of sporadic
ALS patients
Plasmas of
sporadic ALS
patients
Leukocytes of ALS
patients
Leukocytes of ALS
patients

45

19

47
48
48
50
50

Table 2. List of epigenetic enzymes involved in Amyotrophic Lateral Sclerosis.
*Sirtuin cofactor involved in ALS pathology. Adpadted from Bennett et al., Transl Res,
2019.
Class

Enzyme

Histone
Acetyltransferas
es

CBP/p300

Histone
Deacetylases

HDAC1

ELP3

HDAC2
HDAC6

HDAC11
SIRT1
SIRT2
NAD+ *
Histone
Methyltransferas
es

PRMT1

PRMT5

Activity in ALS

Reference

Reduced activity when
interacting with FUS
Required for neuronal
communication and
survival in Drosophila

80

Mislocalizes to cytoplasm
in FUS ALS model
Accumulation in nucleus
is neuroprotective
Levels decrease in spinal
tissue of ALS patients
Promotes SOD1
aggregation
Overexpression is
neuroprotective in mouse
model
Levels increase in the
spinal tissue of ALS
patients
Levels increase in the
muscles of a mutated
SOD1 mouse model
Levels decrease in motor
neurons of a mutated
SOD1 mouse model
Depletion leads to motor
neuron degeneration

103

Overexpression rescues
neurite growth in FUS
model
Reduced methylation of
H4R3, ultimately leading
to gene silencing

126

Genomic instability and
R-loop formation

148

20

85

104
102
106
107
102
105
105
111

127

Chromatin
Modifying

CHD2/Chd
1
POLR2A

Inhibited by TDP-43,
inhibited stress response
required for neuronal
survival
Genomic instability and
R-loop formation

21

145

148

Figure 1. Histone post-translational modifications linked to different
proteinopathies and genes in Amyotropic Lateral Sclerosis. Arrows denote an
increase or a decrease for a given modification in the context of ALS. Adpadted from
Bennett et al., Transl Res, 2019.
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Chapter 2: ALS proteinopathies are connected to distinct histone
post-translational modification landscapes.73,a
2.1 Rationale for studying ALS proteinopathies in Yeast
Is there a role for epigenetics in neurodegenerative disease? Recent evidence
has linked ALS to epigenetic mechanisms (reviewed in18, 152, 153). Thus far, DNA
methylation has been the dominant subject of research on epigenetics of
neurodegenerative disease. Nevertheless, there is evidence for the importance of
histone modification in this context. For instance, overexpression of wild type FUS
induces hypoacetylation of histone H3 on a specific gene promoter.154 Moreover, the
levels of HDAC1, HDAC2 and Sirtuins (a family of class III histone deacetylases) have
been found to be impaired in postmortem ALS tissues.155, 156 Indeed, FUS itself has
been shown to interact with HDAC1 to recruit the latter to sites of DNA damage.157 More
recently, redistribution of wild-type or mutant FUS to the cytoplasm has been associated
with a loss-of-function in the arginine methyltransferase PRMT1 resulting in alterations
in histone PTMs.128 Despite all the evidence for an epigenetic component in ALS, a
comprehensive study of the histone modifications involved in these diseases has not
been carried out to date.
Yeast is a useful model for studying neurodegenerative diseases because it
preserves many neuronal cellular pathways and upon TDP-43 or FUS overexpression it
recapitulates proteinopathies and cytoplasmic foci seen in ALS.89, 90, 158-160 In contrast to
other ALS model systems, yeast are inexpensive, expeditious and easy to work with. In
fact, yeast models have enabled identification of ALS genetic risk factors.161
a

https://doi.org/10.1021/acschemneuro.7b00297
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the human protein ASH1—has been found to suppress the toxicity of TDP-43 inclusions
in a yeast model.162 Furthermore, yeast models for other ALS-related proteinopathies
have also identified chromatin proteins as modifiers of protein aggregation cytotoxicity.89
Here, we exploit FUS and TDP-43 yeast proteinopathy models to identify perturbations
in histone PTMs patterns by way of western blotting using modification-specific
antibodies. To the best of our knowledge, this is the first comprehensive
characterization of histone PTMs in any ALS model. Remarkably, we find distinct
changes in histone modification profiles for each proteinopathy model. Our results
highlight FUS aggregation to be associated with the most pronounced changes in
several histone marks including phosphorylation of histone H2B, phosphorylation and
acetylation on histone H3, as well as histone H4 arginine dimethylation. Furthermore,
we observe a global decrease in gene transcription in the context of FUS proteinopathy.
We also identify more moderate histone PTMs disturbances in cells overexpressing
TDP-43 and α-synuclein. Small increases in the levels of histone acetylation on lysine
12 and 16 on histone H4 as well as a small decrease in the level of trimethylation of
lysine 36 on histone H3 are apparent in the context of TDP-43 overexpression. Overall,
our results highlight a great need for the inclusion of epigenetic mechanisms in the
study of neurodegenerative disease and the search for more effective treatments for
these disorders.
2.2 TDP-43 and FUS proteinopathies elicit distinct perturbations in the histone
PTMs landscape
Using modification-specific antibodies, we have delineated the global epigenetic
make up of TDP- 43 and FUS proteinopathies. To do this, we exploited well-established
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yeast models for ALS.159, 160, 163, 164 Previous investigations have found these show
cytoplasmic foci in 90% of cells in TDP-43 and FUS models.165 Yeast were transformed
with either a control vector or vectors expressing TDP-43 or FUS. Spotting assays on
inducing selective media corroborated growth of control cells and cytotoxicity of TDP-43
and FUS. In our experiments, FUS overexpression was the most toxic, followed by
TDP-43. (Figure 2a,b). Galactose-induced protein expression was verified by western
blotting for both constructs (Figure 2c,d). In liquid culture, cytotoxic phenotypes are
much less severe (Figure 2e). After galactose induction, we harvested and lysed both
control yeast and yeast overexpressing TDP-43 or FUS. The timeframe of cell harvest
for histone modification analysis precedes the point of toxicity in liquid culture (Figure
2e). Cell lysates were subjected to SDS-PAGE to separate histone proteins from all
other proteins. We then probed for individual histone modifications using commercially
available modification-specific antibodies. We selected immunoblotting methods
because of their high sensitivity of detection for low- abundance proteins and
modifications.166 In this work, we focused primarily on histones H3 and H4, as these
histones are most pervasively modified.167 Furthermore, we included histone
modifications involved in both transcriptional activation and repression. Altogether, we
incorporated 24 histone modifications in our experiments. Individual histone
modifications were quantitated by blot image analysis, normalized to the loading control
and compared to the control sample to obtain fold change measurements. Remarkably,
we identified distinct histone PTM panoramas for each proteinopathy (Figure 3). Pvalues were used to assess the statistical significance of observed changes. Due to
large variations observed in some of the histone modifications, the p-values provide a
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better representation of the observed PTM changes than the averages and were thus
used to construct the heat map in Figure 3. Overall, we found TDP-43 overexpression
to be associated with increases in several histone PTMs, while FUS overexpression is
associated with highly significant decreases in histone modification levels. As a positive
control illustrating the potential range of changes on histone modification levels, we
treated wild type cells with the DNA-damage agent bleomycin, which induces both
single-stranded and double-stranded DNA damage.168 We explored the levels of
phosphorylation on histone H2A on serine 129, which is homologous to phosphorylation
on S139 in humans and a notable histone modification occurring in response to a DNA
double strand break.169, 170 After bleomycin treatment, we observe a ~2.5-fold increase
in the phosphorylation of serine 129 in histone H2A (Figure 4). In general, it is important
to note that statistical significance does not correlate with magnitude of the change in
histone PTMs levels. For instance, in the context of TDP-43 overexpression, changes
on histone H3K36me3 levels are highly reproducible and thus significant statistically
(Figure 3), but very modest in magnitude. Altogether, our results suggest the observed
epigenetic changes are specific to each individual proteinopathy and not associated
with general protein aggregation toxicity pathways. Furthermore, we found that ALS
proteinopathies are connected to widespread changes in histone modifications
throughout the genome that are detectable without the need for enrichment of any
particular genomic regions.
2.3 Histone PTM dysregulation in TPD-43 and FUS models
2.31. Histone H3 methylation
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To our surprise, many of the histone H3 methylation sites we probed display
similar modification levels in both control cells and proteinopathy models. In particular,
all degrees of methylation (me1, me2, and me3) on lysine 4 and lysine 79 showed no
changes (Figures 5 and 6). We did not study methylation on lysine 9 because this
modification is not present in budding yeast.171 We note no genome-level disturbances
in the levels of H3K79me3, which along with H3K9me3, H3K27me3 and H4K20me3,
has been implicated in particular genetic loci in other proteinopathies related to ALS.172
However, we found an exception in changes on the levels of di- and tri-methylation of
histone H3 at lysine 36. In yeast, H3K36 is methylated by the methyltransferase Set2,
which can install up to three methyl groups on the lysine side chain.173 Interestingly, the
human counterpart of Set2, SETD2, interacts with huntingtin protein pointing to a
potential role for this modification in neurodegenerative disease.174 H3K36 methylation
has been implicated in transcriptional elongation, suppressing histone exchange and
hyperacetylation as well as promoting maintenance of chromatin structure over coding
regions in order to prevent aberrant transcriptional initiation within coding sequences.175
While the levels of H3K36me2 do not change in FUS and TDP-43 models (Figure 7a),
we found the levels of H3K36me3 were modestly decreased when TDP-43 is
overexpressed (Figure 7b), but remained unchanged in the FUS model.
2.3.2 Histone H3 acetylation and phosphorylation
We observed the most sizeable changes in histone H3 PTMs levels in the
context of FUS overexpression. In particular, we detected a 50% decrease in the levels
of phosphorylation of H3 on serine 10 (Figure 8a). This change in H3S10ph is
unmatched in the TDP-43 overexpression models. H3S10ph has been linked to both
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transcriptional activation and repression. Ipl1, the yeast homolog of the mammalian
Aurora B Kinase, is responsible for its installation.176 Highlighting its importance, this
modification is remarkably conserved throughout the eukaryotic kingdom.177 The striking
alteration in the levels of this modification might point to an important role for Aurora B
Kinase in ALS etiology. Indeed, Aurora B Kinase has been shown to phosphorylate
Ataxin-10, a key protein in Spinocerebellar ataxia type 10, another neurodegenerative
disorder.178 Unfortunately, we are unable to pinpoint if decreases in H3S10ph arise from
alterations in the levels of Ipl1 as antibodies for this protein are unavailable. To clarify
whether the observed alterations in histone modifications are related to protein toxicity
and/or expression levels, we lowered toxic protein expression levels by growing cells on
a combination of galactose and sucrose. Sucrose gets slowly metabolized to glucose,
and glucose in turn represses the galactose promoter.179 First, we verified the
sucrose/galactose setup reduced FUS expression (Figure 9c). Unsurprisingly,
decreased expression of FUS lessened the toxic phenotypes observed on solid and
liquid media (Figure 9a-b, respectively). Indeed, we find lowered levels of FUS resulted
in decreased magnitude of change in the level of phosphorylation of Histone H3 on
Serine 10 (Figure 9d-e).
We also observed important hypoacetylation of H3 on lysine 14 in the FUS model
(Figure 9b). We did not observe parallel acetylation changes in the TDP-43
overexpression model. Furthermore, we detected no alternations in the acetylation
levels of histone H3 on lysine 9, lysine 18 or lysine 27 in either of our proteinopathy
models (Figure 10). Past research linked overexpression of wild type FUS to
hypoacetylation on both K9/K14 in the cyclin D1 gene promoter in human cells.154
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However, as this investigation used an antibody that recognized K9/K14 acetylation in
tandem, it is hard to compare our findings. Generally, hypoacetylation is correlated to a
tighter association between histones and DNA and the establishment of transcriptionally
inactive heterochromatin.180-182 However, it is striking that we did not observe a general
reduction in acetylation for all sites, but rather we determined that FUS proteinopathy is
associated with loss of acetylation at specific histone H3 sites. H3K14ac is involved in
DNA damage checkpoint activation and DNA repair,183, 184 and thus lowered levels
suggest DNA repair is impaired in the FUS model. Furthering this hypothesis, H3K56ac
– an acetylation site in the core domain of H3- is also significantly lowered in the FUS
proteinopathy model (Figure 8c). This modification is required to reinstate chromatin
structure over repaired DNA, and is critical for signaling completion of repair.185 Akin to
H3K14ac, we did not detect statistically significant changes in the levels of H3K56ac in
the TDP-43 overexpression models.
2.3.3 Histone H4 methylation
In conjunction to the changes on H3 modification outlined above, we also
identified a decrease on the levels of dimethylation on arginine 3 on histone H4 in the
FUS model (Figure 11a). This is in agreement with the H3K14 hypo-acetylation we
observe, as H4R3me2 has been associated with H3 acetylation at both lysine 9 and
lysine 14.186 In yeast, Hmt1, the yeast homolog of the protein arginine methyltransferase
1 (PRMT1), catalyzes the formation of H4R3me2.187 PRMT1 has been found to interact
with and methylate FUS, affecting its cellular localization.188-192 Consistent with our
findings, expression and mislocalization of wild type or mutant human FUS in cultured
murine motor neurons has been previously found to lead to nuclear depletion of PRMT1
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and a consequent reduction in the levels of H4R3me2.128 It is possible that FUS is
sequestering Hmt1 and localizing to the cytoplasm resulting in hypo-methylation at this
site. It is also conceivable mislocalized protein sequesters other histone modifiers
resulting in the various changes on histone modification levels we detect. Moreover,
H4R3me2 has been associated with transcriptional activation.193 Together with lowered
acetylation on H3K14 and H3K56, decreased H4R3me2 would suggest a decrease in
gene transcription. We found no statistically significant changes in the level of
H4R3me2 in the TDP-43 model. Furthermore, we observed no alterations in any of the
other histone H4 modifications studied in the FUS overexpression background,
including symmetric dimethylation on R3 (Figure 12).
2.3.4 Histone H4 acetylation
In contrast to observed changes in the FUS model, we encountered modest
hyper-acetylation of histone H4 on lysine 12 and lysine 16 in the TDP-43 proteinopathy
model compared to control (Figure 11b-c). Histone acetylation has been long
correlated with transcriptional activation.194 In yeast, the specific removal of H4K16ac
enables the formation of a heritably silent state,195 and thus increases in this
modification would suggest enhanced gene transcription in the TDP-43 background.
Interestingly, increased levels of H4K12ac have been found in Alzheimer’s disease
mouse models during early development of the disease.196
2.3.5 Histones H2.A & H2.B
We discovered considerable hypo-phosphorylation of histone H2B on threonine
129 in the FUS proteinopathy model (Figure 13). Loss of phosphorylation at this site is
associated with decreased gene expression as well as DNA damage.197, 198 While this
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modification is not conserved in humans, we included it in our analysis as we
anticipated it could yield important information on the biological pathways linked to ALS
pathology. We observed a 50% decrease in the level of H2BT129ph in cells
overexpressing FUS compared to control cells (Figure 13). Changes in this modification
fit together with changes in H3K14ac and H3K56ac (Figure 8b-c) and stress a role for
DNA damage and repair in FUS proteinopathy. Furthermore, activation of poly (ADPribose) polymerase 1 (PARP-1) in response to DNA damage has been found to inhibit
Aurora B Kinase,199 and thus changes in H3S10ph levels in the FUS model would also
correspond with triggering of the DNA damage signaling. Puzzlingly, we found no
significant differences in the levels of phosphorylation on histone H2A on serine 129 in
any of the proteinopathy models (Figure 14). This raises the possibility that the
combination of modifications observed in the FUS model is not occurring in association
to DNA damage, but are instead related to other processes. It is plausible that the
histone modifications we observe arise in association to unidentified defense
mechanisms triggered by the cytotoxicity of the protein aggregates.
2.4 Total RNA levels are decreased in the FUS yeast model
Collectively, many of the alterations on histone modifications observed in the
FUS model point to decreased gene transcription. To further validate this hypothesis,
we chose a straightforward approach in which we extracted and quantitated total RNA
in each proteinopathy model and compared them to control. As we expected, total RNA
levels were lower in the FUS overexpression background compared to control (Figure
15). Together with our histone modification data, we interpret this result to indicate a
global decrease in gene expression occurs in the FUS model. This finding agrees with
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previous investigations, which found transcriptional activity to be decreased in neurons
presenting FUS mislocalization.128 Notably, we observed this effect despite protein
overexpression. As FUS is a RNA-binding protein, it is possible that it sequesters RNA
in protein aggregates. However, we did not observe a similar effect in the context of
TDP-43 overexpression. TDP-43 is also a RNA- binding protein, and thus if the change
in RNA levels resulted from sequestration then this effect should be present in the TDP43 samples as well. While the histone modification changes observed in the TDP-43
model (increases in histone H4 acetylation as well as H3K36me3) support
transcriptional activation, it is possible that the increased gene transcription corresponds
to specific genomic loci and thus it would not be detected by changes in total RNA
levels.
2.5 Histone crosstalk in FUS and TPD-43 yeast models
We present a summary of all observed histone PTMs changes in Figure 16.
Extraordinarily, we found very little overlap between the histone PTM alterations elicited
in the two proteinopathy model. Overall, we found the most and most intense
modification changes to be associated with FUS proteinopathy, followed by TDP-43
proteinopathies. Unsurprisingly, the number and magnitude of changes appear to
correlate with cytotoxicity of protein expression. Remarkably, we only observe
modification increases in the TDP-43. Altogether, our data indicates important
decreases in histone phosphorylation and acetylation are associated with cytotoxic
phenotypes.
Our data also underscores histone crosstalk between modifications and provides
hints regarding the mechanisms of PTM interaction. For instance, we observed
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decreases in both H3S10ph and H3K14ac in the FUS proteinopathy background
(Figure 16). In yeast, H3S10ph has been shown to promote acetylation of H3K14 by
Gcn5 at specific gene promoters.200 Thus, it is not surprising to observe that these two
modifications decrease in tandem. In the context of FUS overexpression, we also
observe decreases in H2BT129ph (Figure 16). Ipl1 –the yeast homolog of Aurora B
Kinase- has been shown to be able to phosphorylate H2B.201 Therefore, decreases in
the phosphorylation of these two sites might be pointing at Ipl1 impairment in FUS
proteinopathy. Lastly, we observed evidence for inter-histone crosstalk, as we identify
decreases in both H4R3me2 and H3K14ac (Figure 16). H4R3me2 has been previously
linked to histone H3 acetylation at both lysine 9 and lysine 14.186 Other correlations
present in our data could arise from yet undiscovered crosstalk processes.
It is important to note that our data is limited to yeast models of ALS, and thus
verification in other model systems is still lacking. Furthermore, it is difficult to establish
causal relationships from our experiments: do changes in histone modifications lead to
disease processes or do disease processes lead to changes in histone modifications?
Issues of causality are a struggle for the field of histone modifications at large.202
Nevertheless, we establish a clear association between strong decreases in histone
phosphorylation and acetylation with most severe cytotoxic phenotypes. Furthermore,
we observe changes in histone PTMs as early as five hours into protein overexpression.
Regardless of causation, histone modification pathways are highly accessible
pharmacologically and thus they hold great promise for disease treatment.
Recent work has targeted several histone ‘writers’ and ‘erasers’ to ameliorate
ALS phenotypes. Notably, HDAC inhibitors have been used with success in mice ALS

33

models.101 In ALS mice models, treatment with an HDAC inhibitor led to neuroprotection
and improved motor function,203 while treatment with phenylbutyrate (a general HDAC
inhibitor) significantly extended survival and improved clinical and neuropathological
phenotypes.116 Our findings highlight further histone modifiers as potential targets for
pharmaceutical intervention. In addition to reversing decreases in histone acetylation,
novel chemical intervention strategies aimed at reversing decreases in histone
phosphorylation and methylation could potentially improve cell survival in the context of
neurodegenerative disease. Based on our results, inhibitors for Protein Phosphatase 1
and 2, which remove H3S10ph,177, 204 as well as inhibitors of JMJD6, a Jumonji domaincontaining protein reported to demethylate H4R3me2,205 could become useful
therapeutic avenues for ALS.
2.5 Conclusions
We have carried out the first comprehensive characterization of histone
posttranslational modifications in any ALS models. Remarkably, we discover that
distinct changes in histone modification profiles for each proteinopathy model
evidencing that histone PTM changes are not associated with general protein
aggregation toxicity pathways. Furthermore, we find widespread changes detectable in
whole genome samples. Our results highlight FUS aggregation to be associated with
the most pronounced changes in several histone marks including phosphorylation of
histone H2B, lysine phosphorylation and acetylation on histone H3, as well as histone
H4 arginine methylation. We also observe a global decrease in gene transcription in the
context of FUS proteinopathy. Furthermore, we identify moderate disturbances in
histone modification patterns in cells overexpressing TDP-43. Our data corroborates
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previous findings in different model systems, while significantly broadening our
knowledge of the epigenetic landscape of neurodegenerative disease. The expanded
set of modifications we present here could uncover novel histone ‘writer’ and ‘eraser’
targets for pharmacological intervention. Overall, our results underscore the potential
importance of epigenetic mechanisms in the occurrence and progression of ALS and
other neurodegenerative diseases and lead to novel, more effective therapies for these
ailments.
2.6 Experimental Methods
Materials. All chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless
otherwise specified.
Yeast Strains, Media, and Plasmids. All yeast were W303a (MATa, can1-100, his311,15, leu2-3,112, trp1-1, ura3-1, ade2-1).90 Yeast were grown in synthetic dropout
media (Clontech Laboratories, Inc., Mountain View, CA). Media was supplemented with
2% glucose, raffinose, or galactose. Vectors encoding TDP-43, FUS, and α-synuclein
(pAG303GAL-TDP-43, pAG303GAL-FUS, and pAG303GAL-α-synuclein-GFP,
respectively) were a gift from A. Gitler. 158, 160, 164 A pAG303GAL-ccdB vector was used
as a control. pAG303GAL-ccdB was a gift from Susan Lindquist (Addgene plasmid #
14133).
Yeast Transformation, Spotting Assays, and Liquid Culture Growth Assay. Yeast
were transformed according to standard protocols using polyethylene glycol and lithium
acetate.206 For spotting assays, yeast were grown to saturation overnight in raffinosesupplemented dropout media at 30ºC. Cultures were diluted 2-fold, serially diluted 2fold, and then spotted in duplicate onto synthetic dropout media containing glucose,
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sucrose galactose or mixtures of sucrose and galactose. Plates were analyzed after
growth for 2-3 days at 30ºC. For liquid culture growth assays, yeast were grown in
galactose-supplemented or sucrose/galactose-supplemented media for 48 hours at
30ºC. Optical density measurements were taken every 24 hours.
Bleomycin Treatment. Wild-type W303a yeast were grown to saturation overnight at
30ºC on YPD media (Dot Scientific, Burton, MI, Cat #DSY20092-1000). Yeast were
standardized to an optical density of 0.3 and grown for 4 hours at 30ºC. Cultures were
then checked to verify log phase growth and treated with 20 µg/ml bleomycin (EMD
Millipore Corp., Billerica, MA, Cat # 203401-10MG) for one hour. After treatment,
cultures were normalized to an optical density of 0.9; 10 mL of cells were then
harvested and frozen at -80ºC.
Protein Overexpression. Protein overexpression in yeast was induced in galactose- or
sucrose/galactose-containing medium for 5 hours (TDP-43 and FUS) or 8 hours (αsynuclein-GFP) at 30ºC. After induction, cultures were normalized to an optical density
of 0.9; 10 mL of cells were then harvested and frozen at -80ºC.
Western Blotting. Frozen yeast cell pellets were thawed and treated with 0.2M NaOH
for 10 minutes on ice, pelleted again and subsequently resuspended in 100 μL 1×SDS
sample buffer and boiled for 10 minutes. Cell lysates were separated using SDS-PAGE
(15%) and then transferred to a PVDF membrane (EMD Millipore, Billerica, MA).
Membranes were blocked using LI-COR blocking buffer (LI-COR Biosciences, Lincoln,
NE) for 1 hour at room temperature. Primary antibody incubations were performed at
4°C overnight. Antibodies used were: rabbit anti-TDP-43 polyclonal (Proteintech,
Chicago, IL, Cat #10782-2-AP), rabbit anti-FUS polyclonal (Bethyl Laboratories,
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Montgomery, TX, Cat#A300-302A), and mouse anti-3-phosphoglycerate kinase (PGK)
monoclonal (Novex, Frederick, MD, Cat#459250). For histone modifications, all
antibodies were purchased from Abcam (Cambridge, MA) unless otherwise specified:
H3 (cat #ab24834), H3K4me1 (cat #ab8895), H3K4me2 (cat #ab7766), H3K4me3 (cat
#ab8580), H3K9ac (cat #ab10812), H3K14ac (Millipore, cat #07-353), H3K18ac (cat
#ab1191), H3K27ac (cat #ab45173), H3K36me1 (cat #ab9048), H3K36me2 (cat
#ab9049), H3K36me3 (cat #ab9050), H3K56ac (ActiveMotif, Carlsbad, CA, cat
#39281), H3K79me1 (Millipore, cat #ABE213), H3K79me2 (cat #ab3594), H3K79me3
(cat #ab2621), H3S10ph (cat #ab5176), H4 (cat #ab10158), H4K8ac (cat #ab15823),
H4K12ac (cat #ab46983), H4K16ac (cat #ab109463), H4K20me1 (cat #ab9051),
H4K20me3 (cat #ab9053), symmetric H4R3me2 (cat #ab5823), H4R3me2 (cat
#ab194696), H2AS129ph (cat #ab15083), and H2BT129ph (cat #ab188292). Blots were
processed using goat anti-mouse and anti-rabbit secondary antibodies from LI-COR
Biosciences (Lincoln, NE) and imaged using an Odyssey Fc Imaging system (LI-COR
Biosciences, Lincoln, NE). All immunoblotting experiments were repeated a minimum of
three times with independent cell samples.
RNA Purification. Yeast were grown and induced in galactose-containing medium for 5
hours (TDP-43 and FUS). 2 x 107 cells were harvested for each sample and treated with
100 U Zymolyase-20T (Nacalai USA, San Diego, CA, cat # 07663-91) for 30 minutes at
30°C. RNA was isolated using the RNeasy Mini Kit from Qiagen (Germantown, MD)
according to the manufacturer’s instructions. Total RNA levels were measured using a
NanoDrop Lite spectrophotometer (Thermo Fisher, Waltham, MA). All experiments were
repeated a minimum of three times with independent cell samples.
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Data Analysis. Densitometric analysis of Western blots was performed using Image
Studio (LI-COR). The signals obtained for histone modifications were normalized to their
respective total histone H3 signals (modification/total H3). These values were then
compared against the control sample values to obtain fold change values
(sample/control), which were used for statistical analysis. A similar procedure was used
to analyze Western blot data from sucrose experiments; the normalized signals were
compared to the sucrose samples' signals. RNA concentrations were normalized
against controls to obtain fold change values used for further analysis.
Statistical Analysis. Statistical analysis of data was performed in R 3.3.1 using the
built-in stats package (R-Project, Vienna, Austria). Significant differences between
sample groups (Control vs. TDP-43, Control vs. FUS, and Control vs. α-synuclein) was
determined using Welch's t-test with p = 0.05 as the cut-off for significance. Error bars
on the graphs represent the standard error of the mean calculated from values obtained
in the data analysis step described above. Figure 1 was constructed from these pvalues, which were transformed according to a previously described method using the
equation, − log 𝑥 ∗ 𝑦, where 𝑥 represents the p-value and 𝑦 represents the sign of the
test statistic.207 Western blot data from sucrose experiments were analyzed using oneway ANOVA, followed by Tukey's test for pairwise comparison of the group means.

38

Figure 2. Yeast expressing TDP-43 and FUS exhibit cytotoxic phenotypes. Spotting assays
depict cell viability (a) without and (b) with galactose induced expression. Western blots confirm
the expression of (c) TDP-43 and (c) FUS in these cells. (e) Growth curve illustrating cell
viability in liquid culture under galactose induction. Error bars indicate the +/- SEM. n=3 for each
cell line. Adapted from Chem, Bennett, et al., ACS Chem. Neurosci, 2018.
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Figure 3. Histone modifications are altered in the context of yeast overexpressing
TDP-43 and FUS. p- values for the ratio of histone H2A, H2B, H3 and H4 PTMs
abundances in yeast strains expressing TDP-43 and FUS relative to control cells are
shown. The scale is based on p-values derived from statistical analysis of Western
blotting experiments. p- values were calculated using a two- tailed t-test with Welch's
modification Green indicates more statistically significant decreased modification levels,
while red indicates more statistically significant increased modification levels. Adapted
from Chem, Bennett, et al., ACS Chem. Neurosci, 2018.
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Figure 4. Levels of histone H2A phosphorylation are Increased in cells treated with
bleomycin. (a) Representative immunoblots showing the levels of H2AS129ph in yeast cells
treated with bleomycin. (b) Quantitation histogram compiling multiple biological replicates,
Graph displays the mean fold change in modification levels for each group based on
densitometric analysis of Western blots. Error bars indicate the +SEM. n ≥ 3. *p < 0.05. Adapted
from Chem, Bennett, et al., ACS Chem. Neurosci, 2018.
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Figure 5. Levels of histone H3 methylation on lysine 4 are not altered in yeast models of
ALS proteinopathies. Representative immunoblots showing the levels of (a) H3K4me1, (b)
H3K4me2, and (c) H3K4me3 for TDP-43 and FUS yeast proteinopathy models, respectively.
Quantitation histograms compiling multiple biological replicates are presented alongside blots.
All graphs display the mean fold change in modification levels for each group based on
densitometric analysis of Western blots. Error bars indicate the +SEM. n ≥ 3 for each
modification. Adapted from Chem, Bennett, et al., ACS Chem. Neurosci, 2018.
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Figure 6. Levels of histone H3 monometylation on lysine 36 And methylation on lysine 79
are not altered in yeast models of ALS proteinopathies. Representative immunoblots
showing the levels of (a) H3K36me1, (b) H3K79me1, (c) H3K79me2, and (d) H3K79me3 for
TDP-43 and FUS yeast proteinopathy models, respectively. Quantitation histograms compiling
multiple biological replicates are presented alongside blots. All graphs display the mean fold
change in modification levels for each group based on densitometric analysis of Western blots.
Error bars indicate the +SEM. n ≥ 3 for each modification. Adapted from Chem, Bennett, et al.,
ACS Chem. Neurosci, 2018.
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Figure 7. The TDP-43 proteinopathy model display decreases in histone H3 trimethylation on lysine 36. Representative immunoblots showing the levels of (a)
H3K36me2, (b) H3K36me3 for TDP-43 and FUS yeast proteinopathy models,
respectively. Quantitation histograms compiling multiple biological replicates are
presented alongside blots. All graphs display the mean fold change in modification
levels for each group based on densitometric analysis of Western blots. Error bars
indicate the +SEM. n = 3-7 for each modification. **p < 0.01, ***p < 0.001. Adapted from
Chem, Bennett, et al., ACS Chem. Neurosci, 2018.
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Figure 8. FUS overexpression correlates with changes in the phosphorylation of
serine 10 and acetylation of lysine 14 and lysine 56 on histone H3. Representative
immunoblots showing the levels of (a) H3S10ph, (b) H3K14ac, and (c) H3K56ac for
TDP-43 and FUS yeast proteinopathy models, respectively. Quantitation histograms
compiling multiple biological replicates are presented alongside blots. All graphs display
the mean fold change in modification levels for each group based on densitometric
analysis of Western blots. Error bars indicate the +SEM. n = 3-6 for each modification.
**p < 0.01, ***p < 0.001. Adapted from Chem, Bennett, et al., ACS Chem. Neurosci, 2018.
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Figure 9. Levels of FUS overexpression correlate with the magnitude of alterations in
serine 10 phosphorylation in histone H3 (a) Spotting assays depict cell viability in glucose,
sucrose, galactose and various ratios of galactose and sucrose. (b) Growth curve illustrating cell
viability in liquid culture in glucose, sucrose, galactose and various ratios of galactose and
sucrose. Error bars indicate the +/- SEM. n=3 for each growth condition. (c) Western blots
assess the expression of FUS in each growth condition. (d) Representative immunoblots
showing the levels of H3S10ph in each growth condition. (e) Quantitation histogram compiling
multiple biological replicates. Graph displays the mean fold change in H3S10ph levels for each
growth condition based on densitometric analysis of Western blots. Error bars indicate the
+SEM. n ≥ 3 for each condition. *p < 0.05. Adapted from Chem, Bennett, et al., ACS Chem.
Neurosci, 2018.
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Figure 10. Levels of Histone H3 Acetylation on Lysine 9, Lysine 18 and Lysine 27 Are Not
Altered in Yeast Models of ALS Proteinopathies. Representative immunoblots showing the
levels of (a) H3K9ac, (b) H3K18ac, and (c) H3K27ac for TDP-43 and FUS yeast proteinopathy
models, respectively. Quantitation histograms compiling multiple biological replicates are
presented alongside blots. All graphs display the mean fold change in modification levels for
each group based on densitometric analysis of Western blots. Error bars indicate the +SEM. n ≥
3 for each modification. Adapted from Chem, Bennett, et al., ACS Chem. Neurosci, 2018.
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Figure 11. FUS and TDP-43 overexpression correlate with changes in arginine dimethylation and lysine acetylation on histone H4. Representative immunoblots
showing the levels of (a) H4R3me2, (b) H4K12ac, and (c) H4K16ac for TDP-43 and
FUS yeast proteinopathy models, respectively. Quantitation histograms compiling
multiple biological replicates are presented alongside blots. All graphs display the mean
fold change in modification levels for each group based on densitometric analysis of
Western blots. Error bars indicate the +SEM. n = 3-6 for each modification, *p < 0.05.
Adapted from Chem, Bennett, et al., ACS Chem. Neurosci, 2018.
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Figure 12. Levels of several histone H4 marks are unchanged In yeast models Of ALS
proteinopathies. Representative immunoblots showing the levels of (a) H4R3me2 (sym), (b)
H4K8ac, (c) H4K20me1, and (d) H4K20me3 for TDP-43 and FUS yeast proteinopathy models,
respectively. Quantitation histograms compiling multiple biological replicates are presented
alongside blots. All graphs display the mean fold change in modification levels for each group
based on densitometric analysis of Western blots. Error bars indicate the +SEM. n ≥ 3 for each
modification. Adapted from Chem, Bennett, et al., ACS Chem. Neurosci, 2018.
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Figure 13. The FUS proteinopathy is associated with changes in histone H2B
phosphorylation levels. Representative immunoblots showing the levels of
H2BT129ph for TDP-43 and FUS yeast proteinopathy models. Quantitation histograms
compiling multiple biological replicates are presented alongside blots. All graphs display
the mean fold change in modification levels for each group based on densitometric
analysis of Western blots. Error bars indicate the +SEM. n ≥ 3 for each modification. *p
< 0.05, **p < 0.01. Adapted from Chem, Bennett, et al., ACS Chem. Neurosci, 2018.
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Figure 14. Levels of histone H2A phosphorylation are not altered in ALS yeast models.
Representative immunoblots showing the levels of H2AS129ph for TDP-43 and FUS yeast
proteinopathy models. Quantitation histograms compiling multiple biological replicates are
presented alongside blots. All graphs display the mean fold change in modification levels for
each group based on densitometric analysis of Western blots. Error bars indicate the +SEM. n ≥
3 for each modification. Adapted from Chem, Bennett, et al., ACS Chem. Neurosci, 2018.
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Figure 15. RNA levels are decreased in a FUS overexpression ALS model Total
RNA levels in yeast control cells as well as cells overexpressing TDP-43 and FUS. All
graphs display the mean fold change in total RNA levels for each group. Error bars
indicate the SEM. n = 3 for each group. *p < 0.05. Adapted from Chem, Bennett, et al.,
ACS Chem. Neurosci, 2018.

52

Figure 16. Yeast models of neurodegenerative disease proteinopathies are
connected to distinct histone post-translational modification landscapes. Green
bars indicate significant decreases, while red bars indicate significant increases relative
to control samples. Error bars indicate the +SEM. n ≥ 3 for each modification. Adapted
from Chem, Bennett, et al., ACS Chem. Neurosci, 2018.
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Chapter 3: Trichostatin A Relieves Growth Suppression and Restores
Histone Acetylation in a FUS ALS Yeast Model.208,a
3.1 ALS, histone PTMs and trichostatin A
HDAC inhibition has arisen as a potential strategy for treating ALS and other
neurodegenerative diseases. For instance, the HDAC inhibitor Scriptaid can clear SOD1
aggregates in vitro.115 Moreover, pan-HDAC inhibitors were found to be neuroprotective
in in vitro and in vivo TDP-43 ALS models.209 Similarly, phenylbutyrate, a general HDAC
inhibitor, improved clinical and phenotypes in an ALS mouse model.116 Trichostatin A
(TSA), a pan class I HDAC inhibitor, decreased motor neuron death and axon
degeneration as well as reduced gliosis in an ALS mouse model.113
Yeast provides an expedient, cost-efficient model to study certain aspects of
neurodegeneration. FUS overexpression in yeast recapitulates several features of ALS
pathology including FUS mislocalization and aggregation.92 Furthermore, in contrast to
mammalian cellular models, yeast FUS ALS models display overt cellular demise allowing
for convenient exploration of chemical tools to prevent cell death. Recent evidence has
tied FUS proteinopathy to the epigenome. FUS overexpression in yeast is associated with
alterations to the histone PTM landscape.1,
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In particular, FUS overexpression is

connected to decreases in the levels of acetylation on Lysines 14 and 56 on Histone H3.73
Histone PTMs are accessible pharmacological targets, and thus we speculated that
chemical interventions aimed at modulating relevant epigenetic changes might lead to
improved cell survival.
a

https://doi.org/10.1021/acs.biochem.1c00455
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3.2 TSA rescues the growth suppression phenotype observed in FUS yeast
3.2.1 W303 yeast
To test if TSA can ameliorate FUS proteinopathy we measured the growth of yeast
overexpressing FUS or a vector control in various concentrations of the drug. DMSO was
used as a vehicle control. Serial dilutions were grown on selective media supplemented
with either glucose or galactose. Glucose suppresses FUS expression, while galactose
activates it. Both FUS and vector control strains grew well on glucose, regardless of drug
condition (Figure 17, left panel). Hence, TSA does not appear to impact yeast growth at
the concentrations used. As previously reported,73,
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FUS overexpression leads to a

dramatic decrease in cell growth compared to a vector control (Figure 17, left panel).
Excitingly, TSA treatment led to amelioration of growth suppression in FUS yeast. Yeast
overexpressing FUS treated with TSA grow better than their untreated and vehicle control
counterparts (Figure 17, black arrows). To semi-quantitatively measure the effect of TSA
treatment on yeast growth in the context of FUS overexpression, we assessed the image
density of the middle spot from each condition and compared it to the corresponding spot
in the vector control (Figure 17, right panel). Yeast overexpressing FUS treated with 2.50
µM TSA grew significantly better than untreated yeast or yeast treated with vehicle control
DMSO (Figure 17, right panel). FUS yeast treated with either 0.625 µM or 1.25 µM TSA
grow better than untreated yeast, but did not reach statistical significance (Figure 17,
right panel).
3.2.2 DPDR yeast
To further validate the effect of TSA treatment, we repeated the experiment in a
different yeast strain. The DPDR1,3 strain is lacking genes for regulation of an ATP-
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binding-cassette that provides multi-drug resistance, rendering them more sensitive to
drug treatments.210 As expected, FUS overexpression leads to strong growth suppression
(Figure 18, left panel), which is rescued by treatment with 2.5 µM TSA (Figure 18, right
panel). Our results establish that interfering with HDAC activity via TSA treatment
ameliorates the growth suppression phenotype associated with FUS overexpression in
yeast.
3.3 TSA does not affect FUS expression or aggregation
We verified that the reduction of growth suppression was not due to changes in
the expression or aggregation of FUS. To test the former, we measured total levels of
FUS expression by Western blotting (Figure 19a). There was no significant difference in
FUS levels in any of the treatment conditions. Through filter-retention assays, we
confirmed that TSA treatment did not affect FUS aggregation (Figure 19b) TSA and other
HDAC inhibitors have been previously shown to trigger expression of Hsp70 which helps
clear FUS aggregates and reduce proteotoxic stress.211,
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However, as we see no

reduction in FUS aggregation, we suspect the toxicity mitigation we observe does not
involve enhanced proteostasis.
3.4 TSA restores histone acetylation in FUS yeast
3.4.1 H3K14 and 56ac
To probe whether detoxification occurred through epigenetic mechanisms, we first
asked if TSA treatment restored levels of H3K14ac. To assess this, we grew yeast in
galactose-supplemented liquid media to elicit FUS overexpression and treated the cells
with no drug, DMSO (vehicle) or 2.50 µM TSA. We selected a concentration of 2.50 µM
TSA based on our solid media growth results (Figure 17). Western blotting followed by
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densitometric analysis of H3K14ac specific bands normalized to the H3 total loading
control yields a fold change for H3K14ac under each condition. Consistent with previous
results73, untreated and DMSO-treated yeast displayed significantly lower levels of
H3K14ac compared to the untreated vector control (Figure 20a). Remarkably, FUS yeast
treated with 2.50 µM TSA showed a significant increase in H3K14ac levels compared to
untreated FUS yeast and DMSO treated FUS yeast. (Figure 20a). TSA treatment
restored H3K14ac levels up to control levels (Figure 20a). In the case of H3K56ac,
acetylation levels were significantly lower in untreated and DMSO-treated FUS yeast
compared to the vector control. As for H3K14ac, TSA restored H3K56ac up to control
levels, with TSA treated yeast showing significantly higher acetylation levels than both
untreated and DMSO treated yeast (Figure 20b). This was surprising because H3K56 is
deacetylated by Hst3 and Hst4, which are insensitive to TSA.213, 214 Acetylation of H3K56
is mediated by the lysine acetyltransferase Rtt109 in concert with the chaperones Vsp75
and Asf1.215, 216 Interestingly, H3K14ac drives Rtt109 to specifically acetylate H3K56ac
via Asf1 binding.216 Through this crosstalk mechanism, it is possible that H3K14ac
recovery is promoting a rise in H3K56ac levels.
3.4.2 TSA does not affect global acetylation level at 2.50 µM
TSA increases global acetylation levels in yeast, but at concentrations higher than
those used in this study. 217, 218 To verify that 2.50 µM TSA did not affect acetylation levels
at other lysine residues not connected to FUS proteinopathy, we measured acetylation
on H4K16 (Figure 21). TSA treatment did not increase acetylation levels on this residue,
suggesting that 2.50 µM TSA restores acetylation only on those modification sites that
are originally impacted by FUS overexpression. To further investigate if 2.50 µM TSA
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raised acetylation levels outside of the context of FUS proteinopathy, we probed for
H3K14ac and H3K56ac in vector control yeast, where the levels of these PTMs are not
decreased. TSA treatment has no significant effect on H3K14ac or H3K56ac levels in
vector control yeast (Figure 22).
3.5 TSA does not restore other histone PTM levels in FUS yeast
As we observed evidence of histone PTM crosstalk, we wondered if other nonacetyl histone modifications that change in the context of FUS proteinopathy would
recover in response to TSA treatment. FUS yeast, regardless of treatment conditions,
retained significantly reduced H3S10ph and H4R3me2asym levels (Figure 23). This
suggests that the decreases in these PTMs are independent of histone acetylation levels.
Furthermore, it establishes that the amelioration of growth suppression elicited by TSA is
not related to changes in the levels of H3S10ph or H3Rme2asym. Akin to histone
acetylation, TSA treatment did not affect neither H3S10ph nor H4R3me2asym in vector
control yeast (Figure 24).
3.6 Conclusions
Collectively, we show that TSA relieves growth suppression in yeast
overexpressing FUS. This mitigation of toxicity is accompanied by restoration of H3K14ac
and H3K56ac levels, but not H3S10ph or H4R3me2asym levels. We did not observe any
changes in FUS expression or aggregation with TSA treatment. To the best of our
knowledge, this is the first report of its kind tying specific histone acetylation sites to ALS
cell demise. Pan-histone acetylation has been shown to increase after HDAC inhibition,
but specific residues were not implicated.113, 219 Furthermore, our data raises the novel
hypothesis that the toxic effect of protein aggregation in neurodegeneration is at least in
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part related to its association with altered histone marks, a notion that is not well
characterized in ALS. We hypothesize reduction of toxicity occurs through modulation of
epigenetic pathways. Very recently, pathogenic FUS has been found to interact with
nucleoporins and impede nucleocytoplasmic transport.220 It is possible that defects in
nucleocytoplasmic transport result in the cytoplasmic mislocalization of Gcn5, the HAT
primarily responsible for H3K14 acetylation,221 leading to decreased H3K14ac levels.
Unfortunately, there are no commercially-available antibodies for yeast Gcn5, which
preclude straightforward cellular localization studies. H3K56ac might be lowered through
crosstalk with H3K14ac or by another mechanism. We speculate impaired H3K14ac and
H3K56ac could then lead to aberrant gene expression and ultimately cell death (Figure
25). However, further investigation is needed to definitively establish such a mechanism.
In conclusion, our results highlight that changes in histone PTMs are closely
associated with the cell demise elicited by FUS proteinopathy. We illustrate the ability to
counter the detrimental effects of protein aggregation on cell survival by modulating
specific histone modification changes via chemical treatment. Our results allude to novel
mechanistic networks involving epigenetics that will enable new treatments for ALS and
other neurodegenerative diseases.
3.7 Experimental methods
Yeast Strains, Media and Plasmids All yeast were W303a (MATa, can1-100,his3-11,
15,leu2,3,11,12,trp1-1,ura3-1,ade2-1).90 DPDR yeast have the same background with the
exception of deletion of pdr1 and pdr3. DPDR yeast were a gift from J. Shorter (University
of Pennsylvania). Yeast were grown in synthetic dropout medium (Clonetech
Laboratories, Mountain View, CA) supplemented with 2% glucose, raffinose or galactose.
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The FUS plasmid (pAG303GAL-FUS) was a gift from A. Gitler (Addgene plasmid no.
29614).92 A control ccdB plasmid, pAG3030GAL-ccdB, was a gift from Susan Lindquist
(Addgene plasmid no. 14133).90 Yeast were transformed using standard poly(ethylene
glycol) and lithium acetate protocols.222
Solid Media Growth Assays Yeast were grown to saturation overnight in raffinosesupplemented dropout media at 30°C. Overnight cultures were diluted 2-fold, then serially
diluted 5-fold. A volume of 2 µL for each dilution was pipetted onto synthetic dropout
medium glucose or galactose containing no treatment, DMSO, 0.625 µM TSA, 1.25 µM
TSA or 2.50 µM TSA. Plates were analyzed after 3-4 days of growth at RT. Images of the
plates were imported into ImageJ (Fiji),223 and the density of the middle spot of each plate
was measured using the oval tool. All experiments were repeated a minimum of three
times with three independently transformed yeast strains.
Protein Overexpression Yeast strains were grown to saturation overnight in raffinosesupplemented dropout media in a shaking incubator at 30 °C and 200 rpm. Overnight
cultures were then diluted to an OD600 of 0.30 in 50 mL of raffinose-supplemented
synthetic dropout media and grown for another 4 hours at 30 °C. Cells were then pelleted
at 850 rcf at 4 °C and washed 3x with sterile distilled water. The pellet was then
resuspended in 50 mL of galactose-supplemented media with DMSO, 2.5 µM TSA or
untreated and grown for 5 hours at 30 °C. After induction, cultures were normalized by
cell count and harvested at 850 rcf at 4 °C for 5 minutes and washed 3X with sterile
distilled water. Yeast were then resuspended in 500 µL sterile distilled water, evenly split
into five microcentrifuge tubes and harvested at 850 rcf at 4 °C for 5 minutes. The
supernatant was removed and the pellets were flash frozen in liquid nitrogen and stored
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at -80 °C. All experiments were repeated a minimum of three times with three
independently transformed yeast strains.
Western Blotting Frozen yeast cell pellets were thawed and treated with 0.2 M NaOH
for 10 minutes on ice, pelleted again, and subsequently resuspended in 100 µL of 1x SDS
sample buffer and boiled for 10 minutes. Cell lysates were separated using SDS-PAGE
(15%) and then transferred to a PVDF membrane (EMD Millipore). Membranes were
blocked using LI-COR blocking buffer (LI-COR Biosciences, Lincoln, NE) for 1 hour at
RT. Membranes were incubated with primary antibodies at 4 °C overnight. Primary
antibodies used were: rabbit anti-FUS polyclonal (Bethyl Laboratories, Montgomery, TX;
cat. no. A300-302A, 1:1,000 dilution), mouse anti-PGK monoclonal (Novex, Frederick,
MD; cat. no. 459250, 1:2,000 dilution), mouse anti-H3 total (Abcam, Cambridge, MA; cat.
no. ab24834, 1:2,000 dilution), rabbit anti-H3S10ph (Abcam, Cambridge, MA; cat. no.
ab5176, 1:1,000 dilution), rabbit anti-H3K14ac (Millipore, cat. no. 07-353, 1:2,000
dilution), rabbit anti-H3K56ac (ActiveMotif, Carlsbad, CA; cat. no. 39281, 1:5,000 dilution)
and rabbit anti-H4R3me2asym (Abcam, Cambridge, MA; cat. no. ab194683, 1:1,000
dilution). Blots were processed using goat anti-mouse and anti-rabbit secondary
antibodies from LI-COR Biosciences (both at 1:20,000 dilution) and imaged using an
Odyssey Fc imaging system (LI-COR Biosciences). All immunoblotting experiments were
independently repeated a minimum of three times. Densitometric analysis of Western
blots was preformed using Image Studio (LI-COR Biosciences). The signals obtained for
histone

modifications

were

normalized

to

their

respective

total

H3

signals

(modification/total H3). These values were then compared with untreated control-sample
values to obtain fold change values (sample/control), which were used for statistical
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analysis. Similarly, FUS bands were compared to Phosphoglycerate Kinase-1 signal
values for normalization.
Filter Retention Assay Filter retention assay procedures were modified from Alberti et
al., 2010.224 Briefly, cells were incubated in spheroblasting solution [1. M D-Sorbitol, 0.5
mM MgCl2, 20 mM Tris - pH 7.5, 50 mM b-mercaptoethanol, 0.5 mg/mL zymolase
(Nacalai Tesque, Kyoto, Japan; cat. no. 07663-91)] for 1 hours at 30 °C while rotating.
The samples were then centrifuged at 800 rcf for 5 min and the supernatant was removed.
The pellets were then resuspended with in 180 µL of lysis buffer [20 mM Tris – pH 7.5,
10 mM b-mercaptoethanol, 0.5% Triton X-100, 2X HALT Protease Inhibitor (Thermo
Scientific, Waltham, MA; cat. no. 78425)] and incubated at room temperature for 10
minutes. The sample was then centrifuged at 21,130 rcf for 2 minutes and 60 µL of the
supernatant was added to the well of 96-well plate, in triplicate. 80 µL of sterile distilled
water was added to the well of each plate. The Bio-Dot vacuum manifold (Bio Rad,
Hercules, CA) was assembled according to manufacturer’s instructions after the cellulose
acetate membrane was soaked in PBS. Any unused wells were covered with tape to
increase vacuum pressure. 100 µL of sample were loaded into wells of the apparatus and
allowed to gravity filter, followed by the addition of 200 µL PBS and gravity filtration. 200
µL of blocking buffer (LI-COR Biosciences) were added and allowed to gravity filter and
then washed twice with 200 µL PBS, which were vacuum filtered. 100 µL of FUS primary
antibody (Bethyl Laboratories, 1:1,000 dilution) was then added and allowed to gravity
filter, followed by three PBS washes which were vacuum filtered. Finally, 100 µL of
secondary antibody was added (anti-rabbit, LI-COR Biosciences, 1:20,000 dilution) and
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allowed to gravity filter, followed by two PBS washes which were vacuum filtered. The
blot was imaged using an Odyssey Fc imaging system (LI-COR Biosciences).
Statistical Analysis Statistical analysis of data was performed in RStudio 1.2.5001 using
the built-in stats package (R-Project, Vienna, Austria). Significant differences between
drug treatment groups were determined using one-way ANOVA followed by Tukey’s test
for pairwise comparison of the group means with p = 0.05 as the cutoff for significance.
Error bars on the graphs represent standard deviation (SD) calculated from values
obtained in the data analysis steps described above. All graphs were constructed with
ggplot2 in RStudio (R-Project, Vienna, Austria).225

63

Figure 17. Trichostatin A relieves growth suppression in a FUS ALS yeast model.
Yeast integrated with a gene encoding FUS or an empty vector were serially diluted 5fold and spotted on glucose (off) or galactose (on) medium in the absence (untreated,
DMSO) or presence of TSA at varying concentrations. Densitometric measurement of
cell density compared to the untreated control is depicted. Box plot whiskers represent
upper and lower quartiles. *** = p < 0.001, ** = p < 0.01. n = 4.
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Figure 18. Trichostatin A relieves growth suppression in DPDR yeast
overexpressing FUS. DPDR yeast integrated with a gene encoding FUS or an empty
vector were serially diluted 5-fold and spotted on glucose (off) or galactose (on) medium
in the absence (untreated, DMSO) or presence of TSA at varying concentrations.
Densitometric measurement of growth compared to the untreated control is depicted. Box
plot whiskers represent upper and lower quartiles and dot represents an outlying data
point. ** = p < 0.01, * = p < 0.05. n = 4.
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Figure 19. Trichostatin A has no effect on FUS expression or aggregation. FUS
expression was measured by Western blotting (A, n = 4), while FUS aggregation was
measured with a filter retention assay (B, n = 6). Histograms compiling multiple biological
replicates display the mean fold change in FUS expression or aggregation based on
densitometric analysis. Error bars represent +SD.
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Figure 20. Trichostatin A restores acetylation on Lysines 14 and 56 on Histone H3
in the yeast FUS ALS model. Representative Western blots displaying the levels of
H3K14ac (A, n = 6) and H3K56ac (B, n = 6) are shown. Histograms compiling multiple
biological replicates are shown alongside blots. Error bars represent +SD. * = p < 0.05,
** = p < 0.01, *** = p < 0.001.
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Figure 21. Trichostatin A treatment has no effect on H4K16ac levels in the yeast
FUS ALS model. A representative Western blot displaying the levels of H4K16ac (n =
6) is shown. A histogram compiling multiple biological replicates is also shown. Error
bars represent +SD
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Figure 22. Trichostatin A has no effect on histone acetylation levels on Histone H3
K14 and K56 in vector control yeast. Representative Western blots displaying the
levels of H3S10ph (a, n = 3) and H3K56ac (b, n = 4) are shown. Histograms compiling
multiple biological replicates are represented alongside blots. Error bars represent +SD.
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Figure 23. Trichostatin A has no effect on H3S10ph or H4R3me2asym levels in the
yeast FUS ALS model. Representative Western blots displaying the levels of H3S10ph
(a, n = 3) and H3K56ac (b, n = 4) are shown. Histograms compiling multiple biological
replicates are represented alongside blots. Error bars represent +SD.* = p < 0.05, ** = p
< 0.01.
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Figure 24. Trichostatin A has no effect on H3S10ph or H4R3me2asym levels in
vector control yeast. Representative Western blots displaying the levels of H3S10ph (a,
n = 3) and H4R3me2asym (b, n = 3) are shown. Histograms compiling multiple biological
replicates are represented alongside blots. Error bars represent +SD.
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Figure 25. Putative mechanism for TSA effects in the FUS ALS yeast model.
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Chapter 4: FUS binds directly binds Nop1 while Ipl1 and Rtt109 are
mislocalized leading to dysregulation of histone post-translational
modification and reduced levels of total RNA.
4.1 Rationale
We have previously reported that various histone PTMs are significantly depleted
in FUS proteinopathy yeast model (Chapter 2),73 and that restoring histone acetylation
via chemical intervention rescues the growth suppression phenotype elicited by FUS
overexpression (Chapter 3). In this Chapter, we explore how FUS overexpression and
aggregation impacts the histone PTM landscape. To accomplish this, we interrogated
the FUS interactome in a yeast proteinopathy model by way of co-immunoprecipitation
(Co-IP) coupled to mass spectrometry (MS)-based proteomics. FUS is a RNA-binding
protein, that is primarily located in the nucleus and is involved numerous cellular
processes including RNA maturation and DNA repair.160, 226 We hypothesize that FUS is
sequestering chromatin proteins and leading to a loss of function, and ultimately
reducing levels of H3S10ph, H3K14ac, H3K56ac and H4R3me2asym.
In a separate approach, we probed for the levels and cellular localization of those
histone modifying enzymes responsible for deposition of histone PTMs connected to
FUS proteinopathy. In particular, we studied Ipl1, Gcn5 and Rtt109, which are
responsible for the deposition of H3S10ph, H3K14ac and H3K56ac, respectively.176, 215,
216, 221

We added a Flag tag to the C-terminal end of these enzymes by PCR targeting

and measured their levels and localization by Western blotting and
immunocytochemistry (ICC), respectively.
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Lastly, we investigated if RNA binding by FUS is necessary for dysregulation of
histone PTMs. A FUS construct with point mutations in its RNA Recognition Motifs (FUS
RRM) that obliterate RNA binding was overexpressed in yeast. FUS RRM is less toxic
compared to wild-type FUS.160 We measured the levels of H3S10ph, H3K14ac,
H3K56ac and H4R3me2asym in yeast overexpressing FUS RRM by Western blotting
and compared them to yeast overexpressing wild-type FUS or a vector control.
Here we show that FUS binds a large number of proteins in yeast, including the
histone methyltransferase Nop1. Furthermore, Ipl1 and Rtt109 are significantly
mislocalized from the nucleus. Interestingly, Ipl1 colocalizes with FUS. Lastly, we find
that it is not necessary for FUS to bind RNA for it to elicit dysregulation of PTMs. FUS
RRM elicits a similar reduction in the levels of H3S10ph, H3K14ac, H3K56ac and
H4R3me2asym as wild-type FUS. Altogether, we present a model where Ipl1 and FUS
are mislocalized to the cytoplasm in FUS yeast from the nucleus, causing the reduction
of histone PTM levels, and these decreased PTMs and FUS-Nop1 binding lead to lower
total RNA levels.
4.2 FUS Co-IP Assay
4.2.1 Putative binding partners of FUS are involved in ATP binding and rRNA
processing
To gain insight into the molecular mechanisms connecting protein
aggregation to histone modification changes, we interrogated FUS’ protein interactome
in yeast by performing a Co-immunoprecipitation experiment (Co-IP) using a FUS
antibody as the bait (Figure 26a). A rabbit polyclonal FUS antibody was covalently
attached to magnetic beads and incubated with lysates from yeast overexpressing FUS.
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As a negative control, we incubated beads conjugated to the FUS antibody with lysates
from yeast overexpressing a vector control. This control accounts for non-specific
protein binding to the FUS antibody. As an additional negative control, we also
incubated non-conjugated “naked” beads with FUS yeast lysates to control for nonspecific binding to the beads themselves. The recovered proteins were separated by
SDS-PAGE and visualized by Silver staining (Figure 27a). There are a number of
distinct protein bands in the FUS lane, while the two control lanes are relatively devoid
of protein. In the FUS sample, there is a prominent band near the 34 kDa molecular
weight marker. Another band between the 43 and 55 kDa molecular weight markers is
also present. The strong band around 55 kDa is likely FUS itself. We confirmed FUS
pulldown via Western Blotting (Figure 27b).
To identify FUS’ binding partners, recovered proteins from two independent CoIP experiments were analyzed by tandem MS. Each trial identified over 2,000 proteins
to interact with FUS. To narrow down proteins of interest, we only considered proteins
that: (1) were among the hits in both trials, (2) had over 40 peptide spectrum matches in
the FUS Co-IP condition, and (3) displayed at least two-fold enrichment over the two
control conditions. A peptide spectrum match refers to the number of times a peptide is
identified, and relates to the abundance of a particular protein in the sample.227 This
filtering process rendered 39 proteins as putative FUS binding partners (Figure 26b;
Table 3). Interestingly, we do not observe Ipl1 or Rtt109 as putative binding partners of
FUS, suggesting that their sequestration to the cytoplasm is not due to direct interaction
between these proteins.
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To better understand what cellular functions FUS proteinopathy impacts, we
submitted our final 39 proteins for pathway analysis with the online tool DAVID.228, 229
The resulting Gene Ontology230 and KEGG 231-233 Pathway annotations are shown in
Table 4. Three of the four top GO biological annotations are involved in rRNA
processing, while the top three molecular function annotations are involved in ATP
binding. Interestingly, a large number of ribosomal proteins were identified as FUS
partners in a GST tagged FUS Co-IP study in 293T cells.234 Using the resulting
annotations, we created an enrichment map Figure 26c. The nodes in the map
represent annotations that were significantly over-represented in the 39 putative binding
proteins, and the nodes were automatically clustered into similar biological processes.
Out of 17 nodes, 11 were related to ATP binding Figure 26c, yellow oval. Interestingly,
many of the nodes that correspond to ATP binding are related to ATP-dependent RNA
helicase activity. Furthermore, six putative binding proteins (Dbp1, Dbp2, Ded1, Mcm4,
Prp43 and Ylr419W) are RNA helicases.235-239 Unsurprisingly, we also find the ATP
binding subunits of Hsp70 chaperone (Ssa1 and Ssa2) among our protein hits.240 FUS
is found in cytoplasmic aggregates and Hsp70 may be present to process such
aggregates. Furthermore, the translational initiation factor Tef1 is also among our
hits.241 Interestingly, Tef1 has a molecular weight of 50 kDa and correspond to the
strong band observed on the Silver stain of the FUS Co-IP between 43 and 55 kDa
(Figure 27). FUS proteinopathy is associated with decreased gene expression, and
Tef1 binding by FUS and nuclear exclusion might contribute to this. The other six nodes
are associated with rRNA processing (Figure 26c, teal oval). Five putative FUS binding
proteins are in each of these six nodes; Utp10, Nop56, Rrp5, Utp22 and Nop1. Rrp5 is
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an RNA binding protein involved in 18S and 5.85S rRNA biogenesis.242 Nop56 is a
nucleolar protein that directs the methylation of pre-rRNA.243 Utp10 and Utp22 are both
members of the small-subunit processome, with the former being involved in the
processing of pre-18SrRNA and the latter being necessary for the export of tRNAs from
the nucleus.244, 245
4.2.2 Nop1 is a FUS binding partner.
We next wanted to identify the distinct 34 kDa band on the silver stain (Figure
27). Out of the 39 proteins of interest, two proteins have molecular weights in the 34
kDa range, Pet9 and Nop1. Pet9 transports ADP from the cytosol to the mitochondria
and ATP in the reverse direction.246 Nop1, the yeast homologue of fibrillarin, is a histone
modifying enzyme that responsible for the methylation of H2AQ105 and involved in the
transcription of rRNA.247, 248 We decided to focus on Nop1 as it relates more directly to
the histone PTM landscape and is involved ribosomal production and processing.245, 249
To verify that FUS binds Nop1, we conducted a FUS Co-IP experiment as
described above, but the recovered proteins were separated by SDS-PAGE followed by
blotting against a Nop1 antibody. The total input was used a positive control and both
control and FUS yeast show Nop1 bands (Figure 28a, lanes 1 and 2). As a negative
control, FUS yeast were incubated with unconjugated beads. We did not observe any
Nop1 binding to naked beads (Figure 28a, lane 3). Importantly, only FUS yeast showed
Nop1 in the Co-IP condition (Figure 28a, lanes 4 and 5). PGK1 was used as a loading
control, and was only present in the input lanes (Figure 28a, lanes 1 and 2). On top of
our proteomic findings, these results provide further evidence that FUS and Nop1 are
interacting directly. For additional confirmation of this interaction, we performed a

77

reverse Co-IP experiment using a Nop1antibody as the bait and probing for FUS via
immunoblotting. We first validated the Nop1 antibody pulls down Nop1 (Figure 28b).
Next, we probed the recovered proteins for FUS (Figure 28c). Expectedly, the input
control only showed FUS in FUS yeast (Figure 28c, lanes 1 and 2) and there is no FUS
signal in yeast incubated with unconjugated beads (Figure 28c, lane 3). We detect FUS
in the Nop1 reverse Co-IP condition in FUS yeast while control yeast showed no FUS
(Figure 28c, lanes 4 and 5). Finally, we visualized Nop1 and FUS in control and FUS
yeast via immunocytochemistry (Figure 28d). In both control and FUS yeast we
observed strong Nop1 staining centered in the nucleus (Figure 28d, first column). As
before, we observe no FUS staining in control yeast and strong cytoplasmic puncta in
FUS yeast (Figure 28d, second column). Importantly, we see yellow puncta in the
merge, evidencing colocalization between FUS and Nop1 (Figure 28d, white arrows).
These results confirm the interaction between FUS and Nop1 and suggest that FUS is
tied to partial redistribution of Nop1. Furthermore, it provides mechanistic insight into
FUS pathology in the proteinopathy yeast model as FUS-Nop1 binding may impede
Nop1 function and reduction in rRNA.
4.3 Expression levels and cellular localization of histone modifying enzymes
4.3.1 Expression levels of histone modifying enzymes are unchanged in FUS
yeast
FUS proteinopathy is connected to changes in H3S10ph, H3K14ac, H3K56ac
levels. These modifications are installed by the enzymes Ipl1, Gcn5 and Rtt109,
respectively. It is possible changes on histone PTM arise from changes in the levels in
the histone modifying enzymes themselves. Unfortunately, this possibility cannot be
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directly tested via immunoblotting as there are no commercially available antibodies for
these enzymes. To circumvent this problem, we attached a Flag tag to the C-termini of
the Ipl1, Gcn5 and Rtt109 genes via PCR targeting.250 Inserts were created with primers
containing the genomic sequence of each enzyme and the 3X Flag – KanMX region of
the pTF270 plasmid (Table 5, Figure 29a). The resulting DNA insert was transformed
into control and FUS yeast using a high efficiency transformation protocol. Insertion was
verified by selection against G418 as well as PCR using forward primers recognizing
the gene of interest and a universal primer recognizing the Flag region of the insert
(Figure 29b).
To measure the expression levels of Ipl1, Gcn5, and Rtt109, we overexpressed
FUS and the vector control in PCR-targeted yeast. We did not observe any differences
in histone modifying enzymes between FUS and control yeast (Figure 30). These
results suggest that dysregulation of histone PTMs is not caused by a reduction in the
levels of the enzymes responsible for their deposition.

4.3.2 Cellular Localization of FLAG-tagged histone modifying enzymes
As the levels of Ipl1, Gcn5 and Rtt109 were not impacted by FUS proteinopathy,
we wanted to explore whether their cellular localization was changed in this context. We
preformed immunocytochemistry (ICC) on FUS and control yeast that were transformed
with either Ipl1-Flag, Gcn5-Flag or Rtt109-Flag. We calculated the percent of nuclear
localization for FLAG-tagged proteins,251 and measured Colocalization with the Manders
Colocalization Coefficient (MCC).252 This measurement calculates the numbers of pixels
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that overlap between two fluorescently labeled images.253 The MCC measurement is
between 0 and 1, where number represents the percentage of overlap.
4.3.2.1 Gcn5 is not significantly depleted from the nucleus
FUS and control yeast transformed with Gcn5-FLAG were imaged (Figure 31).
Expectedly, we do not see any staining for FUS in control yeast, whereas FUS yeast
display robust staining in the cytoplasm (Figure 31a). There is diffuse FLAG staining
throughout the cells with distinct puncta in both control and FUS yeast (Figure 31a). We
did not observe any difference between the percent nuclear FLAG staining between
control and FUS yeast, suggesting Gcn5 is not mislocalized in response to FUS (Figure
31b). We did not observe yellow puncta in the in the “Merge” images in FUS yeast
(Figure 31a), suggesting there is no colocalization between Gcn5-FLAG and FUS. The
MCC measurements validated this, displaying and MCC of ~0.5, meaning that only 50%
of FLAG and FUS overlap (Figure 31c).
4.3.2.2 Rtt109 is mislocalized to the cytoplasm in FUS yeast
We imaged FUS and control yeast transformed with Rtt109-FLAG (Figure 32).
As before, we do not detect any staining for FUS in the control yeast, whereas FUS
yeast display robust staining in the cytoplasm (Figure 32a). There is diffuse FLAG
staining in the throughout the cells with distinct puncta in both control and FUS yeast
(Figure 32a). Remarkably, the percentage of nuclear FLAG staining is significantly
lower in FUS yeast compared to control (Figure 32b), suggesting that lowered
H3K56ac levels may be caused by nuclear exclusion of Rtt109. Similar to Gcn5-FLAG
FUS yeast, we did not observe yellow puncta in Rtt109-FLAG FUS “Merge” image

80

(Figure 32a). Colocalization analysis returned averaged MCC value of ~0.55, meaning
only 55% of FUS and FLAG overlap.
4.3.2.3 Ipl1 is mislocalized from the nucleus and colocalizes with FUS
We imaged FUS and control yeast transformed with Ipl1-FLAG (Figure 33).
Again, we do not see any staining for FUS in control yeast, whereas FUS yeast display
robust staining in the cytoplasm (Figure 33a). There is diffuse FLAG staining
throughout the cells with distinct puncta in both control and FUS yeast (Figure 33a).
Excitingly, the percentage of nuclear FLAG staining is significantly lower in FUS yeast
compared to control (Figure 33b), suggesting that lowered H3S10ph levels may be
caused by nuclear exclusion of Ipl1. Interestingly, we observe yellow puncta in FUS Ip1FLAG yeast, suggesting colocalization between the two fluorophores. (Figure 33a,
yellow arrows). Colocalization analysis calculated an average MCC value of ~0.75,
meaning that 75% of Ipl1-FLAG is overlapping with FUS (Figure 33c). These results
support the hypothesis that cellular mislocalization of Ipl1 is causing the decreased the
levels of H3S10ph in FUS yeast. However, the exact interaction between FUS and Ipl1
remain unclear. The colocalization between the two proteins suggest that Ipl1 is being
sequestered, but our Co-IP results not reveal any direct binding between the two.
4.3.3 Ipl1, Gcn5 and Rtt109 do not bind FUS or Nop1directly
As we observed co-localization between Ipl1 and FUS (Figure 33), but Ipl1 was absent
from our FUS partners proteomic hits, we wondered if Ipl1 interacted with FUS indirectly
via Nop1. We investigated if Ipl1-FLAG was directly interacting with FUS or Nop1 using
the same Co-IP scheme described above. We first confirmed that the FUS Co-IP is
pulling down FUS in yeast expressing Ipl1-FLAG (Supplementary Figure 34a). Next,
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we confirmed that FUS interacts with Nop1 in yeast expressing Ipl1-FLAG
(Supplementary Figure 34b). We then performed a reverse Co-IP using a Nop1
antibody as bait and confirmed that Nop1 pulled down Nop1 in yeast expressing Ipl1FLAG (Supplementary Figure 34c) and that Nop1 pulls down FUS in yeast expressing
Ipl1-FLAG (Supplementary Figure 34d). We also confirmed that FUS and Nop1 are
interacting in Gcn5-FLAG (Figure 35) Rtt109-FLAG (Figure 36) yeast. We then
analyzed recovered proteins from the FUS and Nop1 Co-IPs by probing for FLAG in
Ipl1-FLAG (Figure 37a,b), Gcn5-FLAG (Figure 37c,d) and Rtt109-FLAG (Figure 37e,f)
yeast. The FLAG tag was detected in lysates of control and FUS yeast, but did not
appear in any of the Co-IP conditions (Figure 37a-f). Thus, we conclude that Ipl1 is not
directly interacting with FUS or Nop1, and that it is colocalizing with FUS through an
interaction with another binding protein. Similarly, the lack of interaction between Gcn5
or Rtt109 with FUS or Nop1 suggest that the reduced levels are H3K14ac and H3K56ac
are not caused by sequestration of these respective histone modifying enzymes.
4.4 FUS-RNA binding does not contribute to histone PTM dysregulation
4.4.1 FUS RRM yeast display reduced growth suppression
Next, we investigated if RNA binding by FUS contributes to dysregulation of
histone PTMs. Mutating conserved phenylalanine residues to leucine (F305L, F341L,
F359L, F368L) in the RRM domains abolish FUS’ ability to bind RNA.160 FUS with these
mutations in the RRM domain (hence forth referred to as RRM) still aggregates but is
markedly less toxic.160 We transformed yeast with non-integrating plasmids containing a
galactose inducible gene for FUS, RRM or a vector control. As previously reported,160
FUS overexpression is still very toxic, but growth suppression has mostly been
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eliminated in RRM yeast (Figure 38a). To assure that the reduction of the growth
suppression was due to the mutation and not a lack of FUS expression, we verified FUS
expression via western blotting (Figure 38b).
4.4.2 RNA binding is not necessary for histone PTM dysregulation
Levels of H3S10ph, H3K14ac, H3K56ac and H4R3me2asym were measured in
FUS, RRM and control yeast as described in Chapter 2. Histone acetylation levels on
H3K14 and H3K56 were significantly decreased for FUS and RRM compared to control
(Figure 39a,b). We did not observe a statistical difference in the levels of these two
PTMs between FUS and RRM yeast. Similarly, we observed a significant reduction in
H3S10ph and H4R3me2asym levels in FUS and RRM yeast compared to the control,
with no difference between FUS and RRM yeast (Figure 40a,b). These results support
that dysregulation of histone PTMs is independent of FUS’ ability to bind RNA.
As discussed in Chapter 2, these dysregulated PTM are involved in active gene
expression.73 We measured total RNA levels in the FUS, RRM and control yeast to test
if there is a decrease transcription. Unsurprisingly, we observed an almost 50%
decrease in total RNA in FUS and RRM yeast compared to control, with no difference
between FUS and RRM yeast (Figure 41). These results further confirm that PTM
dysregulation and its impact on gene expression is independent of FUS-RNA binding.
4.5 Conclusions
Altogether, we find that histone PTM dysregulation is independent of FUSRNA binding in a FUS yeast overexpression model. In this context, we also show that
the enzyme modifiers Ipl1 and Rtt109 mislocalize to the cytoplasm explaining the
decrease in the H3S10ph and H3K56ac marks. In contrast, the histone
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acetyltransferase Gcn5 is not redistributed in the context of FUS overexpression. Thus,
we speculate that reduction in H3K14ac is occurring via histone crosstalk. Indeed,
H3S10ph has been previously shown to drive H3K14ac.254 However, we cannot exclude
the possibility that increased HDAC activity is leading to the loss of H3K14ac.
Remarkably, Ipl1 colocalizes with FUS, but it absent from our interactome results and
thus we believe it does not bind FUS directly. Interestingly, Rrp5, an RNA-binding
protein among our FUS binding partner results, has been found to associate with
Ipl1.255, 256 It is possible that Rrp5 binds to both FUS and Ipl1, and serves as the bridge
between these two proteins. However, further investigation is needed to definitely
establish this scenario.
We also establish that FUS directly binds Nop1. Nop1 has been identified as the
methyltransferase responsible methylation of H2AQ105, a histone mark linked to the
recruitment of RNA Polymerase I and rRNA biogenesis.248 Unfortunately, we are not
able to measure the levels of H2AQ105me in our FUS yeast as there is no commercially
available antibody for this modification. Intriguingly, recruitment of Nop1 to rDNA is
dependent on H3K56ac.257 Dysregulation of H3K56ac and FUS-Nop1 binding suggest
that decreased rRNA biogenesis could be contributing to FUS toxicity in yeast models.
Strengthening this hypothesis, FUS has been implicated in the response to DNA
damage caused by topoisomerase-I. FUS localizes to sites of stalled RNA Polymerase I
to modulate rRNA biogenesis.258 Moreover, fibroblasts harvested from FUS ALS
patients are hypersensitive to topoisomerase-I DNA damage, suggesting a role for
rRNA biogenesis in ALS.
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Our working model involves Ipl1 being sequestered from the nucleus through
indirect interaction with FUS leading to reduced levels of H3S10ph. In a parallel
mechanism, Rtt109 mislocalization leads to the decrease of H3K56ac levels. We
postulate that H3K14ac levels are lowered through histone crosstalk with H3S10ph. In
sum, histone PTM dysregulation and direct interaction between FUS and Nop1 results
in reduced gene expression and negative cellular outcomes in the context of FUS
proteinopathy. These mechanisms appear to be independent of FUS’ ability to bind
RNA. A schematic representation of the mechanisms linking FUS proteinopathy to the
epigenome is shown in Figure 42.
Our studies agree with previous findings in various ALS/FTD model systems.
Furthermore, our results shed some light into the mechanisms linking protein
aggregation to negative cellular outcomes, and highlight the role of histone PTMs and
histone modifiers in disease processes. While it is important to note that our studies are
limited to yeast models, and thus, verification in other model systems is still necessary,
our results underscore histone modifiers as potential targets for pharmaceutical
intervention in the treatment of ALS. Novel chemical intervention strategies aimed at
histone modifiers such Aurora B kinase p300/CBP could potentially improve cell survival
in the context of neurodegenerative disease. Our investigation also enables several
interesting questions. For instance, how is Rtt109 is ejected from the nucleus? It is
possible that nucleocytoplasmic transport defects elicited by FUS are excluding Rtt109
from the nucleus,259 but again, further investigation is required. Furthermore, how do
identified FUS binding partners contribute to FUS pathology? Of particular interest is the
RNA-binding protein Rrp5 and its possible role in the interaction between FUS and Ipl1.
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Lastly, what is the role of rRNA biogenesis in ALS? Recent evidence has revealed the
FUS is recruited to rDNA after DNA damage caused by topoisomerase-I, and FUS
aggregation and export from the nucleus may be preventing this repair mechanism and
contribute to ALS/FTD pathology.258
Specific histone PTM alterations are tied to FUS proteinopathy, though the
molecular mechanisms behind this association are unclear. We illuminate direct and
indirect interactions connecting protein aggregation to the epigenome. We have shown
that FUS does not need to bind RNA to elicit changes in histone PTMs. Furthermore,
FUS proteinopathy is linked to mislocalization of the histone kinase Ipl1 and histone
acetyltransferase Rtt109 to the cytoplasm, leading to reduction of H3S10ph and
H3K56ac levels. In contrast, the levels and the cellular localization of the histone
acetyltransferase Gcn5 is unchanged; H3K14ac might be lowered through histone
crosstalk. We establish that FUS directly binds the histone modifier Nop1. Dysregulation
of H3S10ph, H3K14ac and H3K56ac as well as FUS binding to Nop1 are potentially
contributing to reduced gene expression and FUS cytotoxicity. Our results highlight the
contribution of histone PTMs and histone modifiers to ALS and other neurodegenerative
diseases and reveal novel targets for therapeutic intervention.
4.6 Experimental methods
Yeast Strains, Media and Plasmids All yeast were W303a (MATa, can1-100,his3-11,
15,leu2,3,11,12,trp1-1,ura3-1,ade2-1).90 Yeast were grown in synthetic dropout medium
(Clonetech Laboratories, Mountain View, CA) supplemented with 2% glucose, raffinose
or galactose. The integrating FUS plasmid (pAG303GAL-FUS) was a gift from A. Gitler
(Addgene plasmid no. 29614).92 A control integrating ccdB plasmid, pAG3030GAL-ccdB,
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was a gift from Susan Lindquist (Addgene plasmid no. 14133).90 The non-integrating
plasmids 426Gal-FUS-RRM-YFP (Addgene plasmid no. 29608), 426Gal-FUS-YFP
(Addgene plasmid no. 20592) and paG426Gal-ccdB (Addgene plasmid no. 14155) were
gifts from A. Gitler and Susan Lindquist, respectively. Yeast were transformed using
standard poly(ethylene glycol) and lithium acetate protocols.222
Transformation of yeast with FLAG-tag histone modifying enzymes via PCR
targeting We designed primers recognizing the FLAG and KanMX sequence in the
pTF268 plasmid (Addgene plasmid no. 44095) in the 5’ and 3’ ends were created with 40
base overhangs recognizing the end of either Ipl1, Gcn5 or Rtt109 up to stop codon
(forward primer) and the immediate bases after the stop codon (reverse primer, Table 4).
The primers were then used in a PCR reaction (Phusion High-Fidelity PCR Kit, New
England BioLabs, Ipswich, MA, Cat. No. E0553L) using the pTF268 plasmid as a template
to create transforming insert. The inserts were then used to transform FUS and control
yeast using a high efficiency yeast transfer protocol.250 We selected for transformed
colonies by plating yeast on synthetic dropout media plates containing 450 µg/mL G418.
Homologous recombination with the target gene was confirmed by PCR using yeast
lysate as the template with a forward primer recognizing an area of the gene of interest
and a reverse primer recognizing the Flag sequence (Table 4).
Protein Overexpression Yeast strains were grown to saturation overnight in raffinosesupplemented dropout media at 30 °C and 200 rpm. Overnight cultures were then diluted
to an OD600 of 0.30 in galactose-supplemented synthetic dropout media and grown for 5
hours at 30 °C. Yeast cultures were then standardized to the lowest OD600. Cells were
then pelleted at 850 rcf at 4 °C and washed 3x with sterile distilled water and harvested.
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The supernatant was removed and the pellets were flash frozen in liquid nitrogen and
stored at -80 °C.
Serial dilution growth assays Growth suppression for FUS RRM constructs was
measured by spotting assay, yeast were grown to saturation overnight in raffinosesupplemented dropout media at 30°C. Overnight cultures were diluted 2-fold, then serially
diluted 5-fold. Yeast were spotted onto synthetic dropout medium containing glucose or
galactose with a frogger. Yeast were grown for 3 to 4 days before imaging.
Western blotting Frozen yeast cell pellets were thawed and treated with 0.2 M NaOH
for 10 minutes on ice, pelleted again, and subsequently resuspended in 100 µL of 1x
SDS sample buffer and boiled for 10 minutes. Cell lysates were separated using SDSPAGE and then transferred to a PVDF membrane (EMD Millipore). Membranes were
blocked using LI-COR blocking buffer (LI-COR Biosciences, Lincoln, NE) for 1 hour at
RT. Membranes were incubated with primary antibodies at 4 °C overnight. Primary
antibodies used were: rabbit anti-FUS polyclonal (Bethyl Laboratories, Montgomery, TX;
cat. no. A300-302A, 1:1,000 dilution), mouse anti-PGK monoclonal (Novex, Frederick,
MD; cat. no. 459250, 1:2,000 dilution), mouse anti-H3 total (Abcam, Cambridge, MA;
cat. no. ab24834, 1:2,000 dilution), rabbit anti-H3S10ph (Abcam, Cambridge, MA; cat.
no. ab5176, 1:1,000 dilution), rabbit anti-H3K14ac (Millipore, cat. no. 07-353, 1:2,000
dilution), rabbit anti-H3K56ac (ActiveMotif, Carlsbad, CA; cat. no. 39281, 1:5,000
dilution), rabbit anti-H4R3me2asym (Abcam, Cambridge, MA; cat. no. ab194683,
1:1,000 dilution), mouse anti-a-Tubulin (1:10,000), mouse anti-Flag M2 (cat. no. F3165)
and mouse anti-Nop1 (Invitrogen, Waltham, cat. no. 28F2). Blots were processed using
goat anti-mouse and anti-rabbit secondary antibodies from LI-COR Biosciences (both at
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1:20,000 dilution) and imaged using an Odyssey Fc imaging system (LI-COR
Biosciences). All immunoblotting experiments were independently repeated a minimum
of three times. Densitometric analysis of Western blots was preformed using Image
Studio (LI-COR Biosciences). The signals obtained for histone modifications were
normalized to their respective total H3 signals (modification/total H3). These values
were then compared with untreated control-sample values to obtain fold change values
(sample/control), which were used for statistical analysis. Similarly, Flag bands were
compared to a-Tubulin signal values for normalization.
Co-Immunoprecipitation Control and FUS yeast were grown until an O.D. of ~0.8 and
harvested by centrifugation at 850 rcf at 4 °C for 5 minutes, followed by washing two
times with sterile water. The resulting pellet was spheroplasted by resuspension in 500
µL of spheroplasting solution (1.2 M D-Sorbitol, 0.5 mM MgCl2, 20 mM Tris-pH 7.5, 50
mM b-mercaptoethanol, 0.5 mg/mL Zymolyase-100T) with constant rotation at 30 °C for
one hour, followed by harvesting at 800 rcf for 5 minutes at room temperature. The
resulting pellet was then resuspended in 200 µL lysis buffer (20 mM Tris-pH 7.5, 10 mM
b-mercaptoethanol, 0.5% Triton X-100, 2X HALT Protease Inhibitor) and incubated for
10 minutes at room temperature, followed by centrifugation at 4000 rcf for 5 minutes.
The resulting supernatant was used immediately for Co-IP. FUS or Nop1 antibodies
were conjugated to M270 Dynabeads and the co-immunoprecipitation was completed
using the Dynabeads Co-Immunoprecipitation Kit according to the manufacturer’s
specifications using the highest stringency washes (Invitrogen, Waltham, MA, cat. no.
14321D). Resulting proteins were analyzed via Western blotting. For samples analyzed
by mass spectrometry, the bead-cell lysis slurry was washed four times with sterile
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filtered PBS and submitted for MS analysis (NYU Proteomics Core). Briefly, the protein
were digested on beads, by reducing with DTT at 57 °C for 1 hour followed by alkylation
with Iodoacetmaide at room temperature for 45 minutes and digested with sequencing
grade Trypsin overnight. The samples were then de-salted using a C-18 membrane and
washed three times with 0.1% TFA. Samples were then eluted with 0.5% acetic acid
and dried in a SpeedVac. The sample was then reconstituted in 0.5% acetic acid. The
samples were then separated by LC using an EASY-nLC 1220 (ThermoScientific).
Peptides were gradient eluted from the column directly to the Orbitrap Eclipse using a 1
hour gradient (Solvent A: 2% acetonitrile, 0.5% acetic acid; Solvent B: 80% acetonitrile,
0.5 acetic acid). High resolution full MS spectra were acquired with a resolution of
240,000, an AGC target of 1,000,000, with a maximum ion time of 60 ms and a scan
range of 400 to 1500 m/z. All MS/MS spectra were collected using the following
instrument parameter: in the ion trap, AGC target of 2,000, maximum ion time of 18 ms,
one microscan, 2 m/z isolation window, fixed first mass of 110 m/z and NCE of 27.
MS/MS spectra were searched against a Uniprot Yeast database using Sequest within
Proteome Discoverer 1.4. Proteins of interest were determined by considering any
protein that overlapped in the two trials and had a PSM over 40 and was at least twofold enriched compared to the controls.
Immunocytochemistry FUS and control yeast containing either Ipl1-Flag, Gcn5-Flag
or Rtt109-Flag were imaged using a standard protocol.260 Briefly, cells were fixed for 15
minutes at constant rotation in 1 mL 4% paraformaldehyde solution (Ted Pella,
Reeding, CA, cat. no. 18501; in 0.1 M sucrose), followed by 2 washes in 1 mL KPO4
and 1 wash with 0.1 M KPO4/1.2M sorbitol. Cells were the resuspended in 1 mL of 0.1
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M KPO4. Yeast were then spheroplasted for 12~13 minutes in 0.1 M KPO4, 0.3 M bmercaptoethanol and 0.1 mg/mL Zymolase-100T, followed by two washes with 0.1 M
KPO4, harvested by 1 minute centrifugation in a microcentrifuge. Cells were
resuspended in 50 µL 0.1 M KPO4. 15 µL of cells were then adhered to Teflon coated
slides that were coated with 0.1% poly-lysine (Epredia, Portsmouth, NH, cat. no. 86010) and the supernatant aspirated off. The slide was immediately submerged into ice
cold methanol for 6 minutes, followed submersion into room temperature acetone,
quickly air dried. The cells were then blocked for 30 minutes with 25 µL PBS-BSA (150
µM Bovine Serum Albumin, 0.05 M KPO4, 0.15 M NaCl, 30 mM NaN3). The cells were
then incubated with primary antibody overnight (1:400 for FUS, 1:100 for FLAG),
followed by 5 washes with blocking buffer, 1.25 hours incubation with secondary
antibody (anti-rabbit AlexaFluor-488, 1:500, anti-mouse AlexaFluor-586, 1:1000), 5
washes with blocking buffer and finally two washed sterile filtered PBS. All volumes
were 25 µL/ well and all steps after addition of secondary antibody took place in the
dark. The cells were mounted with 5 µL Fluoromount-G Mounting Medium with DAPI
(Invitrogen, Waltham, MA, cat. no. 00-4959-52). The slides were images on a Zeiss
LSM 800 confocal microscope at 63x magnification using the DAPI, AF488 and AF55
lasers. Laser intensity was kept constant between control and FUS samples. The
resulting images were processed using ImageJ.261 Nuclear intensity was calculated
from each image by thresholding the DAPI image until only the nucleus was in view,
selecting the area and superimposing it over the FLAG channel and measuring the
mean fluorescence intensity and area. Whole cell FLAG intensity was measured by
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thresholding the FLAG image until only the cells were in view, selecting the area and
measuring. Cytoplasmic intensity was then calculated using the formula:251
Cytoplasmic Intensity = (Whole Cell Mean x Whole Cell Area) – (Nuclear Mean x Nuclear area)

and percent nuclear localization was calculation using the formula:251
%Nuclear = Nuclear Intensity/(Cytoplasmic Intensity + Nuclear Intensity)

FUS and Flag Colocalization was measured with the JACoP plugin for the FUS and
Flag channels.252 The threshold for the images was set to 100 so only the puncta were
selected for calculating MCC.
Statistical Analysis Statistical analysis of data was performed in RStudio 1.2.5001 using
the built-in stats package (R-Project, Vienna, Austria). Significant differences between
nuclear intensity and histone modifying enzymes levels were determined using Welch’s t
test with p = 0.05 as the cutoff. Significant differences between FUS, RRM and control
groups were determined using one-way ANOVA followed by Tukey’s test for pairwise
comparison of the group means with p = 0.05 as the cutoff for significance. Error bars on
the graphs represent standard deviation (SD) calculated from values obtained in the data
analysis steps described above. All graphs were constructed with ggplot2 in RStudio (RProject, Vienna, Austria).225
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Table 3. Putative FUS Binding Partners.

Gene
Symbol
ACC1
BEM2
DBP1
DBP2
DED1
FAS2
HHF1
HSC82
MCM4
MSS116
MYO2
NOP1
NOP56
OLA1
PAB1
PET9
PMA1
PMA2
PRP43
RPO21
RRP5
SAM1
SAM2
SSA1
SSA2
SSB2
TCB1
TCB3
TEF1
TOR1

Protein Name
Acetyl-CoA Carboxylase
Rho GTPase Activating Protein
ATP-dependent RNA helicase
ATP-dependent RNA helicase
ATP-dependent RNA helicase
Fatty acid synthase
Histone H4
Cytoplasmic chaperone – Hsp90
Helicase component of MCM
Transcription elongation factor
Type V myosin motor
Histone methyltranserfase
C/D snoRNP complex component
P-loop APTase
Poly(A) binding protein
Mitochondrial ADP/ATP carrier
P2-type H+ ATPase
P2-type H+ ATPase
RNA helicase
RNA polymerase II subunit
RNA binding protein
S-adenosylmethionine synthase
S-adenosylmethionine synthase
Nuclear transport ATPase – Hsp70
Hsp70 ATP-binding protein
Ribosome chaperone ATPase
Lipid-binding ER protein
Cortical ER protein
Translational elongation factor
Kinase subunit of TORC1
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UniProt
Molecular
Accession
weight
Number
(kDa)
Q00955
250.2
P39960
245.3
P24784
112.9
P24783
61
P06634
65.5
P19097
206.8
P02309
11.4
P15108
80.8
P30665
104.9
P15424
76.2
P19524
180.6
P15646
34.4
Q12460
56.8
P38219
44.1
P04147
64.3
P18239
34.4
P05030
99.6
P19657
102.1
P53131
87.5
P04050
191.5
Q05022
193
P10659
41.8
P19358
42.2
P10591
69.6
P10592
69.4
P40150
66.6
Q12466
133.5
Q03640
171
P02994
50
P35169
281

TY1A-OL
TY1BPR1
URA2
UTP10

Structural constituent of VLPs
Polyprotein processed to make
Gag, RT, PR and IN
Carbamoylphosphate synthetase
Component of small subunit
processome
UTP22
Component of small subunit
processome
VPS1
GTPase required or vacuolar
sorting
YHB1
Nitric oxide oxioreductase
YHR020W Prolyl-tRNA synthetase
YLR419W Putative helicase
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Q92392
P0C2I9

49
198.4

P07259
P42945

244.9
200

P53254

140.4

P21576

78.7

P39676
P38708
Q06698

44.6
77.3
162.9

Table 4. Gene Ontology and KEGG Pathway terms associated with putative FUS
binding proteins.
GO Biological Pathway
Term
GO:0006364: rRNA processing
GO:0031167: rRNA methylation
GO:0010501: secondary structure unwinding
GO:0042254: ribosome biogenesis
GO:0006556: S-adenosylmethionine biosynthetic process
GO:0090344: negative regulation of cell aging
GO:0000451: rRNA 2'-O-methylation
GO:0042759: long-chain fatty acid biosynthetic pathway
GO:0006885: regulation of pH
GO:0090158: endoplasmic reticulum membrane organization
GO:0000390: spliceosomal complex disassembly
GO:0006413: translational initiation
GO:0006555: methionine metabolic process
GO:0060304: regulation of phosphatidylinositol dephosphorylation
GO:0051453: regulation of intracellular pH
GO:0010468: regulation of gene expression
GO:0000462: maturation of SSU-rRNA from tricistronic rRNA transcript
GO:0006409: tRNA export from the nucleus
GO:0030490: maturation of SSU-rRNA
GO Molecular Function
Term
GO:0005524: ATP binding
GO:0000166: nucleotide binding
GO:0004004: ATP-dependent RNA helicase activity
GO:0003729: mRNA binding
GO:0004386: helicase activity
GO:0016887: ATPas activity
GO:0003676: nucleic acid binding
GO:0003723: RNA binding
GO:0046872: metal ion binding
GO:0030515: snoRNA binding
GO:0005544: calcium-dependent phospholipid binding
GO:0004478: methionine adenosyltransferase
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P-Value
3.50E-04
5.80E-04
7.10E-04
1.80E-03
2.00E-02
2.00E-02
2.60E-02
2.60E-02
3.30E-02
3.90E-02
3.90E-02
4.30E-02
4.60E-02
4.60E-02
5.20E-02
7.70E-02
8.10E-02
8.90E-02
9.50E-02
P-Value
1.60E-09
1.90E-09
1.00E-05
7.00E-05
1.00E-04
3.80E-04
1.30E-03
9.30E-03
1.00E-02
1.10E-02
1.50E-02
1.50E-02

GO:0033592: RNA strand annealing activity
GO:0051082: unfolded protein binding
GO:0016787: hydrolase activity
GO:0008553: hydrogen-exporting ATPase activity, phosphorylative
mechanism
GO Cellular Component
Term
GO:0010494: cytoplasmic stress granule
GO:0005739: mitochondrion
GO:0030686: 90S preribosome
GO:0032040: small-subunit proccessome
GO:0005886: plasma membrane
GO:0005654: nucleoplasm
GO:0000329: fungal-type vacuole membrane
GO:0005844: polysome
GO:0005737: cytoplasm
GO:0036464: cytoplasmic ribonucleoprotein granule
GO:0031428: box C/D snoRNP complex
GO:0005832: chaperonin-containing T-complex
GO:0005730: nucleolus
KEGG Pathway
Term
sce03400: Spliceosome
sce04141: Protein processing in endoplasmic reticulum
sce03008: Ribosome biogenesis in eukaryotes
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2.30E-02
2.40E-02
2.70E-02
3.80E-02
P-Value
2.20E-05
4.00E-05
1.50E-04
3.30E-04
3.00E-03
3.00E-03
1.10E-02
1.80E-02
1.90E-02
2.60E-02
3.80E-02
6.90E-02
9.70E-02
P-Value
7.10E-03
5.30E-02
5.80E-02

Table 5. Primers used in the PCR Targeting study.
Primers Used for Insert Creation
Gcn5-

Forward

TAAAGTAAAAGAAATACCTGAATATTCTCACCTTATTGATGGTGGAGGCTCTAGAGACTA

Flag

Reverse

TCGAAAGGAATAGTAGCGGAAAAGCTTCTTCTACGCATTATTAAACTGGATGGCGGCGTT

Rtt109-

Forward

GCTAAAACCGCGTAAAAAAGCTAAAGCCTTGCCTAAAACTGGTGGAGGCTCTAGAGACTA

Flag

Reverse

TCGATGCTACATACGTGTACTAAATAATAAATATCAATATGTATCATTAAACTGGATGGCGGCGTT

Ipl1-Flag

Forward

GATACTAAGAAACAAGCCCTTTTGGGAAAATAAGCGGTTAGGTGGAGGCTCTAGAGACTA

Reverse

TCGATGCTACATACGTGTACTAAATAATAAATATCAATATGTATCATTAAACTGGATGGCGGCGTT

Primers Used for Insert Verification
Universal Reverse

TTAAACTGGATGGCGGCGTT

Gcn5 Forward

GCCGAATGTACAATGGCGAG

Rtt109 Forward

AAATCAGCCGGTTCCTGCAA

Ipl1 Forward

TAGAATGCGCCTTGGAGACG

*All primers are listed in 5’ to 3’ order.
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Figure 26. Putative binding partners of FUS are involved in rRNA processing and
ATP Binding. A) Schematic representation of co-immunoprecipitation experiments
using a FUS antibody as bait. B) Diagram portraying putative FUS binding partners
filtering. C) Enrichment map created from GO Annotations and KEGG Pathways
associated with putative FUS binding partners in yeast. Nodes highlighted in the yellow
oval correspond to annotations related to ATP binding and nodes highlighted in the teal
circle correspond to annotations involved in rRNA processing.
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Figure 27. A large number of proteins co-immunoprecipitate with FUS. FUS
antibody was used as a bait in a Co-IP experiment. The recovered proteins were
separated on a SDS-PAGE gel and Silver stained for visualization (a). A number of
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unique bands are present in the FUS Co-IP compared to the vector and bead alone
controls, including a large band near the 34 kDa region. Verification that FUS was coimmunoprecipitated was asses via Western blotting and probing with a FUS antibody. n
= 3.
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Figure 28. Nop1 directly interacts with FUS. A) Recovered proteins from a Co-IP using
a FUS antibody as bait were probed for Nop1 via Western Blotting. n = 3. B) Recovered
proteins from a Reverse Co-IP using a Nop1 antibody as bait were probed for Nop1 via
Western Blotting. n = 3 C) Recovered proteins from a reverse Co-IP using a Nop1
antibody as bait were probed for FUS via Western Blotting. n = 3. D) FUS or control yeast
were imaged by immunofluorescence with antibodies recognizing Nop1 (red), FUS
(green) and counterstained with DAPI (blue). Examples of Nop1 and FUS colocalization
are highlighted with white arrows. n = 15.
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Figure 29. Production of inserts for FLAG tag transformation and subsequent
insertion were verified by 1% agarose gel electrophoresis followed by staining
with ethidium bromide. n = 3.
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Figure 30. Levels of histone modifying enzymes do not change in the context of
FUS proteinopathy. The levels of Ipl1 (A), Gcn5 (B) and Rtt109 (c) were measured in
control and FUS yeast by Western blotting and probing against FLAG. a-Tubulin was
used as a loading control. Histograms compiling multiple biological replicates display
the mean fold change in FUS expression or aggregation based on densitometric
analysis. Error bars represent +SD. n = 3.
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Figure 31. Gcn5-FLAG does not mislocalize from the nucleus. FUS and control
yeast containing Gcn5-Flag were imaged with immunofluorescence with antibodies
recognizing Flag (red) and FUS (green) and counter stained with DAPI (blue, A). The
percent of Flag in the nucleus was calculated and represented as a histogram (B).
Colocalization between Flag and FUS in FUS yeast was calculated using the JACoP
plugin and correlation coefficients were averaged and represented as histogram (C). n =
15.
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Figure 32. Rtt019-Flag is mislocalized from the nucleus. FUS and control yeast
containing Rtt109-Flag were imaged with immunofluorescence with antibodies
recognizing Flag (red) and FUS (green) and counter stained with DAPI (blue, A). The
percent of Flag in the nucleus was calculated and represented as a histogram (B).
Colocalization between Flag and FUS in FUS yeast was calculated using the JACoP
plugin and correlation coefficients were averaged and represented as histogram (C). n =
15, *** = p < 0.001.
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Figure 33. Ipl1-FLAG mislocalizes from the nucleus and colocalizes with FUS.
FUS and control yeast containing Ipl1-Flag were imaged with immunofluorescence with
antibodies recognizing FLAG (red) and FUS (green) and counter stained with DAPI
(blue, A). The percent of Flag in the nucleus was calculated and represented as a
histogram (B). Examples of Ipl1-FLAG and FUS colocalization are shown with yellow
arrows. Colocalization between FLAG and FUS in FUS yeast was calculated using the
JACoP plugin and correlation coefficients were averaged and represented as histogram
(C). n = 15, *** = p < 0.001.
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Figure 34. FUS and Nop1 directly interact in Ipl1-FLAG yeast. The recovered
proteins from a FUS Co-IP in control and FUS yeast transformed with Ipl1-FLAG were
analyzed by Western blot and probed for FUS (a), Nop1 (b,). Similarly, the recovered
proteins from Nop1 reverse Co-IP in control and FUS yeast transformed with Ipl1-FLAG
were analyzed by Wester blotting and probed for FUS (c) and Nop1 (d). n = 3.
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Figure 35. FUS and Nop1 directly interact in Gcn5-FLAG yeast. The recovered
proteins from a FUS Co-IP in control and FUS yeast transformed with Gcn5-FLAG were
analyzed by Western blot and probed for FUS (a), Nop1 (b,). Similarly, the recovered
proteins from Nop1 reverse Co-IP in control and FUS yeast transformed with Gcn5FLAG were analyzed by Wester blotting and probed for FUS (c) and Nop1 (d). n = 3.
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Figure 36. FUS and Nop1 directly interact in Ipl1-FLAG yeast. The recovered
proteins from a FUS Co-IP in control and FUS yeast transformed with Rtt109-FLAG
were analyzed by Western blot and probed for FUS (a), Nop1 (b,). Similarly, the
recovered proteins from Nop1 reverse Co-IP in control and FUS yeast transformed with
Rtt019-FLAG were analyzed by Wester blotting and probed for FUS (c) and Nop1 (d). n
= 3.
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Figure 37. FUS and Nop1 do not interact with Ipl1-FLAG, Gcn5-FLAG or Rtt109FLAG. The recovered proteins from a FUS Co-IP and Nop1 reverse Co-IP in control
and FUS yeast transformed with Ipl1-FLAG (a & b), Gcn5-FLAG (c & d) or Rtt109-FLAG
(e & f) were analyzed by Western blot and probed for FLAG. n = 3.
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Figure 38. Yeast overexpressing RRM display less growth suppression than yeast
overexpressing wild type FUS. Spotting assays depict cell viability without and with galactose
induced expression. Western blots confirm the expression of FUS in these cells. n = 4.
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Figure 39. Levels of H3K14ac & H3K56ac are significantly reduced in FUS and RRM
yeast. Representative immunoblots showing the levels of H3K14ac (A, n = 7) & H3K56ac (B, n
= 7) for FUS and RRM yeast. Quantitation histograms compiling multiple biological replicates
are presented alongside blots. All graphs display the mean fold change in modification levels for
each group based on densitometric analysis of Western blots. Error bars indicate the +SD. ** =
p < 0.01.
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Figure 40. Levels of H3S10ph & H4R3me2asym are significantly reduced in FUS and
RRM yeast. Representative immunoblots showing the levels of H3S10ph (A, n = 8) &
H4R3me2asym (B, n = 6) for FUS and RRM yeast. Quantitation histograms compiling multiple
biological replicates are presented alongside blots. All graphs display the mean fold change in
modification levels for each group based on densitometric analysis of Western blots. Error bars
indicate the +SD. * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
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Figure 41. RNA Levels Are Decreased in FUS and RRM yeast. Total RNA levels in
yeast control cells and cells overexpressing FUS and RRM. Graph displays the mean
fold change in total RNA levels for each group. Error bars indicate +SD. n = 4. ** = p <
0.01.
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Figure 42. Putative mechanism of how FUS is dysregulating histone PTMs and
total RNA levels.
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Chapter 5: Histone H3 Phosphorylation at Serine 10 is Dysregulated in
Cellular Models of C9orf72 Expansion
5.1 Rationale for studying for histone phosphorylation in the context of C9orf72
ALS
A hexanucleotide repeat expansion (HRE, GGGGCC) between the first two
exons in the C9orf72 gene is the most common cause of familial ALS,262, 263 and has
been found in roughly 15% of sporadic cases.264 In general, the C9orf72 gene in healthy
individuals contains up to 30 HRE; ALS patients carry hundreds to thousands of
repeats.263, 265, 266
HREs in C9orf72 are thought to cause ALS through three pathogenic
mechanisms: haploinsufficiency of C9orf72, toxic accumulation of RNA transcribed from
the HREs and non-canonical repeat-associated non-ATG-dependent translation of the
HRE RNA.264, 267, 268 This non-canonical translation can happen from either the sense or
anti-sense strand, and produces the dipeptide repeat (DPRs) proteins poly-GP, polyGA, poly-GR, poly-PA and poly-PR. The arginine containing peptides are the most
toxic.89, 269 It is now well established DRPs interfere with nuclear-cytoplasmic transport,
contributing to HRE toxicity.89, 269-272 Although, to date, there is no research studying
how DPRs may impact the epigenome.
Alterations to the histone PTM landscape have been observed in various ALS
models.1, 18, 35, 73, 273-275 For instance, reduced levels of histone acetylation, methylation
and phosphorylation have been observed in SH-SY5Y ALS proteinopathy models.274
Recently, significantly reduced levels of global tri-methylation at lysine 9 on histone H3
(H3K9me3) were discovered in a C9orf72 mouse model.275 Furthermore, significantly
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altered levels of histone acetylation, methylation and phosphorylation in TDP-43 and
FUS yeast models. 73 Here, we show that H3S10ph levels are considerably increased in
yeast overexpressing the DPR PR50. Remarkably, we find a similar increase in
H3S10ph levels in induced pluripotent stem cells (iPSCs) and fibroblasts derived from
C9orf72 patients. We further show that Aurora B Kinase is enriched in the nucleus of a
C9orf72 fibroblast line. Additionally, knockdown of Ipl1, the enzyme responsible for
HS10 phosphorylation in yeast, reduces H3S10ph alterations and rescues the growth
suppression phenotype. Our results suggest that H3S10ph alterations play a role in
C9orf72 pathology, and highlight Aurora B kinase as a potential target for treatment of
ALS.
5.2 Overexpression of the dipeptide repeat protein PR50 is toxic in yeast
While inexpensive, time-efficient and easy to work with, yeast proteinopathy
overexpression models recapitulate key proteinopathy features.89, 90, 159, 160, 164 We have
previously exploited FUS and TDP-43 ALS yeast models to uncover associations with
altered histone post-translational modification profiles.73 To characterize changes to the
histone PTM landscape occurring in the context of C9orf72 ALS, we overexpressed the
DPR PR50 in yeast. This model system has the advantage of isolating toxicity attributed
to the DPR -as opposed to precursor RNA species- because it is codon optimized to not
contain the hexanucleotide repeat expansions found in C9orf72.89 Moreover, yeast do
not have a C9orf72 homolog, and thus there is no interference from a “loss of function”
mechanism.89
We overexpressed the DPR PR50 in yeast in the presence of galactose and
compared them to control yeast that were transformed with ccdB, a nonsense protein
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acting as a vector control. As previously reported, PR50 overexpression is highly toxic
(Figure 43a).89 The overexpression of FLAG-tagged PR50 was verified via Western
blotting (Figure 43b).
5.3 Histone phosphorylation and PR50 yeast
5.3.1 H3S10ph levels are significantly increased in PR50 yeast
To assess histone modification levels, yeast overexpressing PR50 and a vector
control were subjected to Western blot analysis probing for histone post-translational
modifications (PTM). PR50 expression was induced for 8 hours, as PR50 expression
peaks at this time and precedes growth suppression (Figure 44). We surveyed a variety
of histone modifications (Figure 45a). Remarkably, we observe an almost 2-fold
increase in H3S10ph levels in PR50 yeast compared to control (Figure 45b).
5.3.2. H3S10ph levels are tied to PR50 overexpression
H3S10ph is linked to both transcriptional activation and silencing176. Ipl1, the
yeast homologue of the mammalian Aurora B kinase, is responsible for installing this
modification.276 Unfortunately, in the context of yeast cells, we were unable to determine
whether the increase in H3S10ph arises from alterations in the levels of Ipl1 because
antibodies for this protein are unavailable. To clarify if altered H3S10ph levels are tied to
PR50 overexpression, we decreased PR50 levels by growing cells in varying ratios of
sucrose and galactose. Sucrose gets slowly metabolized to glucose, and glucose in turn
represses the galactose promoter. We first verified these conditions reduced PR50
expression (Figure 46b). Expectedly, decreased levels of PR50 lessened growth
suppression in solid media, and as galactose concentration increased, so did growth
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suppression (Figure 46a). Importantly, we find that lowering PR50 expression resulted in
a decreased magnitude of change on H3S10ph (Figure 46c).
5.4. H3S10ph levels are increased in C9orf72 human models
5.4.1 H3S10ph levels in iPSCs
Based on our findings in the yeast model, we wondered if H3S10ph levels are
altered in human C9orf72 models. First, we compared H3S10ph levels in induced
pluripotent stem cells (iPSC) derived from an ALS patient with expanded HREs
compared to an age/sex matched control. Excitingly, H3S10ph levels were
approximately 50% higher in histones isolated from the ALS patient (Figure 47a). To
further validate that the rise in H3S10ph levels is due to the HRE in C9orf72 and not any
other difference between the ALS sample and control, we exploited two C9orf72 ALS
iPSC lines, C9n1 and C9n6, for which an isogenic control is available. Surprisingly, we
not find a significant difference between the C9n1 ALS line and its isogenic control
(Figure 47b). However, we did observe a significant increase in H3S10ph levels
between the C9n6 ALS line and its isogenic control (Figure 47b). The reasons for the
divergence in results from different cell lines is unclear, but it’s possible that there is less
PR expression. The results from our yeast experiments suggest the PR drive the rise in
H3S10ph levels, so it stands to reason the C9n1 line is not sufficiently expressing the
DRP.
5.4.2 H3S10ph levels in fibroblasts
We also measured the levels of H3S10ph in a fibroblast line derived from an
C9orf72 ALS patient and an age and sex matched control. We observed significantly
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higher levels in the C9orf72 line compared to the control (Figure 47c). Our results
suggest that elevated H3S10ph levels are a hallmark of C9orf72 ALS.
5.5 Aurora B Kinase is enriched in the nucleus of C9orf72 fibroblasts
Aurora B Kinase is responsible for phosphorylating H3S10. Hence, increased
levels of H3S10ph could point to increased levels of Aurora B kinase in the nucleus. To
determine whether the increase in H3S10ph arises from alterations in the levels of
Aurora B kinase, we isolated the nuclear fraction from C9orf72 fibroblasts and age
matched controls. We then measured the measured the levels of Aurora B Kinase in the
nuclear fraction by Western blotting with a commercially-available Aurora B Kinasespecific antibody. Intriguingly, we found that Aurora B Kinase levels are two-fold
enriched in C9orf72 fibroblasts compared to its control (Figure 48). This result points to
a potential role for Aurora B Kinase and histone phosphorylation in C9orf72 ALS.
5.6 Reducing H3S10ph levels in PR50 yeast relieves toxicity
5.6.1 Knockdown of Ipl1 rescues the growth suppression in PR50 yeast
Our results in fibroblast cell lines suggested that manipulation of the levels or the
activity of Aurora B kinase could counter negative cellular outcomes. However, the lack
of an obvious phenotype in human cellular models complicates these experiments.
Opportunely, the overt cell death observed in PR50 yeast models plus the genetic tools
available for S. cerevisiae enable expedient testing of this hypothesis. We investigated if
lowering H3S10ph levels via reduction of kinase levels would reduce the toxicity
observed in PR50 yeast. Ipl1, the enzyme responsible for phosphorylation H3S10 in
yeast,176 is an essential gene and cannot be knocked out.277 To knock down Ipl1, we
exploited the Decreased Abundance by mRNA Perturbation (DAmP) yeast library.278
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DAmP yeast contain have compromised alleles of genes by inserting a kanamycin
resistance gene in the 3’ untranslated region of gene, effectively reducing transcription 4
to 10 fold.
We overexpressed PR50 in Ipl1 DAmP yeast and the DAmP parental strain,
BY471. All lines grew normally on glucose, where the plasmid is not expressed (Figure
49.a, left panel). Unsurprisingly, PR50 overexpression resulted in strong growth
suppression in the parental strain compared to the vector control (Figure 49.a, right
panel). Expression of PR50 was confirmed by western blotting (Figure 49.b).
Remarkably, we observed growth protection in Ipl1 DAmP, with growth similar to the
vector controls (Figure 49.a, right panel).
5.6.2 Knockdown of Ipl1 reduces H3S10ph levels in PR50 yeast
Expectedly, the parental strain yeast overexpressing PR50 displayed significantly
higher H3S10ph levels compared to controls (Figure 50.b). Excitingly, we observed that
Ipl1 DAmP yeast overexpressing PR50 displayed H3S10ph levels similar to those of
control (Figure 50.a). These results support that Ipl1 and H3S10ph are contributing to
the growth suppression observed in PR50 yeast, and that lowering levels of this
H3S10ph may be a potential treatment option for C9orf72 ALS.
5.7 Conclusions
HREs in the C9orf72 gene are the most common genetic cause of both familial
and sporadic ALS.267 HREs in C9orf72 lead to the production of dipeptide repeat
proteins (DPRs), including proline-arginine (PR). Here, we exploited a yeast model to
survey the histone PTM landscape in the context of PR50 overexpression. Remarkably,
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we observed a large increase in the levels of H3S10ph in PR50 yeast compared to
controls. The H3S10ph mark is an important PTM involved in gene regulation.176, 279
Interestingly, we have observed H3S10ph dysregulation in a FUS overexpression yeast
model of ALS, but there we observed a decrease in the levels of the PTM.73
Remarkably, we have found FUS to secluded from the nucleus in the FUS
overexpression model (unpublished), but our results in fibroblasts and Ipl1 DAmP yeast
suggests the opposite in the context of C9orf72 HRE pathology. This strongly suggests
that this PTM is associated with ALS pathology.
To expand on our yeast model results, we measured the levels of H3S10ph in
isolated histones from various human in vitro ALS models. Importantly, H3S10ph levels
rise in iPSCs and fibroblasts derived from C9orf72 ALS patients. This agreement
between models strongly supports that increased H3S10ph levels contribute to DPR
pathology. Of particular interest is the increase observed in the C9n6 iPSC cell line
compared to an isogenic control. Perplexingly, we did not observe the same rise in
H3S10ph levels in the C9n1 line compared to its isogenic control. Based on our results
in the yeast model, we believe that the alteration to histone phosphorylation is due to
PR. The PR DPR is derived from the antisense strand of the HRE in C9orf72.264, 280
DPRs derived from the antisense strand are less abundant then DRPs derived from the
sense strand.264, 281 It has also been recently shown that PR has a dose dependent
effect on nuclear-cytoplasmic transport in regards to both concentration and length.269 It
is possible that the C9n1 line had lower levels of PR, or even that the DPR was shorter
in length, which may account for the lack of a rise in H3S10ph levels.
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We hypothesized that Ipl1/Aurora B Kinase was being trapped in the nucleus,
leading to the increase of H3S10ph levels. We observed that Aurora B Kinase was
enriched in the nuclear fraction of C9 fibroblasts, supporting our hypothesis. It is
possible that Aurora B Kinase is being trapped in the nucleus either by lack of export or
increased import. Hayes and colleagues showed that DPRs disrupted nuclearcytoplasmic transport through interaction with Importin b and cargo loading, not through
clogging of the nuclear pore complex. They also observe that passive transport into the
nucleus was increased in the presence of PR for proteins that can passively transport
into the nucleus,269 such as Aurora B Kinase.282 Alternatively, PR has been found to
localize to the nucleus, eject HP1a and alter constitution of heterochromatin.283 This
change in heterochromatin was associated with increased levels of H34Kme3, leading
to the toxic accumulation of expressed repetitive elements and double-stranded RNA.
This change to chromatin structure may also contribute to the rise in H3S10ph, although
HP1a is not conversed in yeast and cannot explain the rise in H3S10ph levels we
observe in the PR50 overexpression model.
Altered gene expression has been reported in C9orf72 ALS patients.284, 285 As
H3S10ph is an important regulator of transcription, it is possible that dysregulation of
the PTM is leading to altered gene expression in PR associated C9orf2 pathology.
Alternatively, H3S10ph is also a mark that begins mitosis in eukaryotes.286 Increasing
levels of this mark may be forcing the cell into division, which may be particularly toxic
to neurons in the G0 stage.287, 288 Interestingly, Aurora B Kinase has been found to be
overexpressed in cancer cells, helping them to rapidly divide.289 The elevated levels of
nuclear Aurora B Kinase and H3S10ph may be contributing to PR toxicity. Aurora B
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inhibitors have been started to be used in the treatment of cancer,290 and potent
inhibitors of Aurora B Kinase are currently available.291-294 Our results identify Aurora B
as possible target for C9orf72 ALS treatment, and provide the added benefit of wide
availability of safe drugs. Overall, our results support the role for an epigenetic
mechanism contributing to PR and C9orf72 ALS pathology, adding to a growing body of
research of epigenetics in ALS.1, 18, 73, 273, 274
We reveal an increase in the phosphorylation of Histone H3 on Serine 10
associated with C9orf72 expansions in yeast models, iPSCs and fibroblasts derived
from patients. We hypothesize that alterations in H3S10ph contribute to the cellular
demise observed in C9orf72 ALS. In particular, we postulate that the toxic effect of
protein aggregation is related to its association to altered histone marks. Our model
invokes protein aggregation leading to the retention and enhancement of Aurora B
kinase’s activity in the nucleus. In turn, this causes disruptions in the levels of H3S10ph
across the genome, resulting in heterochromatin disruption, aberrant regulation of
specific genes and cell cycle re-entry.
5.7 Experimental methods
Materials All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless
otherwise specified.
Yeast Strains, Media and Plasmids W303a (MATa, can1-100,his3-11,
15,leu2,3,11,12,trp1-1,ura3-1,ade2-1)90 yeast were grown in synthetic media dropout
medium (Clontech Laboratories, Mountain View, CA) supplemented with 2% glucose,
raffinose or galactose. BY4741 (MATa, his3D1, leu2D0, met15D0, ura3D0) and Ipl1
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DAmP yeast278 were grown in same media without ammonium sulfate (US Biologics,
Memphis, TN, Cat No. Y2030). The PR50 plasmid (pAG303-Gal-PR50) was a gift from
A. Gitler (Addgene plasmid no. 84905).89 A control ccdB plasmid, pAG303Gal-ccdB,
was a gift from Susan Lindquist (Addgene plasmid no. 14133).90 W303 yeast were
transformed using standard poly(ethylene glycol) and lithium acetate protocols.222
BY4741 and Ipl1 DAmP yeast were transformed using a high efficiency protocol.295
Serial Dilution Assays Yeast were grown to saturation overnight in raffinosesupplemented dropout media at 30 °C. Overnight cultures were diluted 2-fold, then
serially diluted 2-fold, then serially spotted onto synthetic dropout media supplemented
with glucose, sucrose, galactose or a combination of sucrose and galactose. Plates
were analyzed after growth for 3-4 days at 30 °C.
PR50 Overexpression in Yeast PR50 overexpression in yeast was induced in
galactose- or sucrose/galactose-containing medium at 30 °C. After induction, the PR50
and ccdB control cultures were normalized to the same optical density and cell aliquots
were harvested, snap frozen in liquid N2 and stored at -80 °C. All experiments were
repeated a minimum of three times with three independently transformed strains.
Yeast Lysis and Western Blotting Frozen yeast cell pellets were thawed and treated
with 0.2 M NaOH for 10 minutes on ice, pelleted again, and subsequently resuspended
in 100 µL of 1x SDS sample buffer and boiled for 10 minutes. Cell lysates were
separated using SDS-PAGE (12, 18% or 4-20%, Bio-Rad, Hercules, CA, Cat No.
4561094) and then transferred to a PVDF membrane (EMD Millipore). Membranes were
blocked using LI-COR blocking buffer (LI-COR Biosciences, Lincoln, NE) for 1 hour at

127

RT. Membranes were incubated with primary antibodies at 4 °C overnight. Primary
antibodies used were: mouse anti-Flag M2 (Cat. No. F3165, 1:1,000 dilution), mouse
H4 total (Abcam, Cambridge, MA, Cat. No. ab10158), mouse anti-H3 total (Abcam,
Cambridge, MA; Cat. No. ab24834, 1:2,000 dilution), rabbit anti-H3S10ph (Abcam,
Cambridge, MA; cat. no. ab5176, 1:1,000 dilution). Blots were processed using goat
anti-mouse and anti-rabbit secondary antibodies from LI-COR Biosciences (both at
1:20,000 dilution) and imaged using an Odyssey Fc imaging system (LI-COR
Biosciences). All immunoblotting experiments were independently repeated a minimum
of three times. Densitometric analysis of Western blots was preformed using Image
Studio (LI-COR Biosciences). The signals obtained for histone modifications were
normalized to their respective total H3 signals (modification/total H3). These values
were then compared with untreated control-sample values to obtain fold change values
(sample/control), which were used for statistical analysis.
Induced Pluripotent Stem Cell Culture C9 iPSC (subject ID NDS00239) and the age
and sex matched control (subject ID NS00242) were obtained from the NINDS Human
Cell and Data Repository. C9n1 (subject ID CS29iALS-C9xx), C9n6 (subject ID
CS52iALS-C9xx) and their respective isogenic control lines (subject IDs CS29iALSC9n1.ISOxx & CS52iALS-C9n.ISOxx) were obtained the Cedars Sinai
Biomanufacturing center. iPSCs were cultured on Matrigel Matrix (Corning, Corning,
NY, Cat. No. 354277) coated 6-well plates with mTeSR1 (StemCell, Vancouver,
Canada, Cat. No. 85850) supplemented with Y-27632 (StemCell, Vancouver, Canada,
Cat. No. 72302) and 100 U/L Penicillin-Streptomycin (Gibco, Amarillo, TX, Cat. No. 15140-122) at 37 °C and 5% CO2. Cells were passaged with 1 U/mL Dispase (StemCell,
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Vancouver, Canada, Cat. No. 07923) at ~75% confluency. During passaging, 10~20
million cells were harvested by centrifugation at 400 g and 4 °C for 5 minutes, followed
washing with 10 ml sterile DPBS (Gibco, Amarillo, TX, Cat. No. 14190144) two times.
The resulting pellet was flash frozen in liquid N2 and stored at -80 °C. Each line was
harvested at least three times. The morphology of the iPSCs were checked at each
feeding to ensure purity.
Fibroblast Cell Culture The C9 fibroblast line (Male, Age at Biopsy – 51) and its
control (Male, Age at Biopsy – 39) were a gift from Jeffery Rothstein. Cells were
cultured in T-75 flasks treated for cells culture (Greiner, Kremsmunster, Austria, Ca. No.
07-000-225) in DMEM with Glutamax (Gibco, Amarillo, TX, 10-566-016) supplemented
with 14% FB Essence (Avantor, Central Valley, PA, Cat. No. 10803-034) and 100 U/L
Penicillin-Streptomycin (Gibco, Amarillo, TX, Cat. No. 15-140-122) at 37 °C and 5%
CO2. Cells were passaged with 0.25% Trypsin (Gibco, Amarillo, TX, 15-050-065) at
~75% confluency. During passaging, 5~15 million cells were harvested by centrifugation
at 400 g and 4 °C for 5 minutes, followed washing with 10 ml sterile DPBS (Gibco,
Amarillo, TX, Cat. No. 14190144) two times. The resulting pellet was flash frozen in
liquid N2 and stored at -80 °C. Each line was harvested at least three times. The
morphology of the fibroblasts was checked at each feeding to ensure purity.
Histone Isolation Histone were isolated from C9 cultures by standard acid
extraction.296, 297 Briefly, cell pellets were lysed in Nuclear Extraction Buffer (NIB, 15 mM
Tris-HCl, 15 mM NaCl, 60 mM KCl, MgCl2, 1 mM CaCl2, 250 mM sucrose, 1 mM DTT,
0.5 mM AEBSF, 5 nM Microcystin) + 0.2% NP-4 for 10 (iPSCs) or 15 (fibroblasts)
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minutes on ice at a 10:1 vol/vol ratio, followed by three washes with NIB at 1,000 g for 5
min at 4 °C at a 10:1 vol/vol ratio. The pellet was then resuspended in a 5:1 vol/vol ratio
of 0.4 N H2SO4 and incubated with constant rotation for 4 hours at 4 °C. Cellular debris
was removed by centrifugation at 3,400 g for 5 min at 4 °C, twice; each time the
histone-containing supernatant was transferred to a fresh tube. Histones were then
precipitated with 100% TCA O/N at 0°C. Histones were then pelleted by centrifugation
at 3,400 g for 5 min at 4 °C, and washed with 0.1 HCl in acetone, followed by a final
wash in pure acetone. The pellet was allowed to air dry completely and was then
dissolved in nuclease free water. Protein concentration was measured with a Bradford
Assay (Bio-Rad, Hercules, CA, Cat. No. 5000205). Samples were standardized to 0.07
µg/µL. Histone purity was assessed by Coomassie (Bio-Rad, Hercules, CA, Cat. No.
1610400) staining following SDS-PAGE on an 18% gel. H3S10ph levels on purified
histones was then measured by Western blotting as described above.
Nuclear Extraction The nuclear fraction was isolated from fibroblasts using a hypotonic
solution.298 Briefly, cell pellets (~5 million cells) were resuspended in 500 µL of
hypotonic buffer (20 nM Tris-HCl, 10 mM NaCl, 3 mM MgCl2) and incubated on ice for
15 min, followed by addition of 25 µL of 10% NP-40 and vortexed on high for 4 °C. The
sample was then centrifuged for 10 min at 3,000 rpm at 4 °C, the supernatant
(containing the cytoplasmic fraction) was removed and saved, while the pellet
(containing the nuclear fraction) was resuspended in Cell Extraction Buffer (10 mM Tris
- pH 7.4, 2 mM Na3VO4, 100 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10% glycerol, 1
mM EGTA, 0.1% SDS, 1 mM NaF, 0.5% deoxycholate, 20 mM Na4P2O7) and incubated
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on ice for 30 min, with vortexing at 10 min intervals. The nuclear fraction was then
centrifuged for 30 min at 14,000 g at 4 °C for 30 min and supernatant (containing
protein) was saved and protein concentration was measured with a Bradford Assay
(Bio-Rad, Hercules, CA, Cat. No. 5000205) and standardized. Aurora B Kinase levels
were measured by Western blotting as described above with an Aurora B Kinase
specific antibody (Abcam, Cambridge, MA, ab2254, 1:1000 dilution) and H3 total
(Abcam, Cambridge, MA; Cat. No. ab24834, 1:2,000 dilution).
Statistical Analysis Statistical analysis of data was performed in RStudio 1.2.5001 using
the built-in stats package (R-Project, Vienna, Austria). Significant differences between
PR50 yeast (W303, BY4741 & Ipl1 DAmP), iPSCs and fibroblasts were determined using
Welch’s t test with p = 0.05 as the cutoff. Significant differences between sucrose tuning
treatment groups were determined using one-way ANOVA followed by Tukey’s test for
pairwise comparison of the group means with p = 0.05 as the cutoff for significance. Error
bars on the graphs represent standard deviation (SD) calculated from values obtained in
the data analysis steps described above. All graphs were constructed with ggplot2 in
RStudio (R-Project, Vienna, Austria).225
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Figure 43. Overexpression of PR50 is highly toxic in yeast. Yeast integrated with a
gene encoded FUS or an empty vector were serially diluted 5-fold and spotted on
glucose (off) or galactose (on) medium (A, n = 3). Representative Western blots
showing the expression of PR50 (B, n = 3).
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Figure 44. PR50 expression peaks at eight hours. The optical density of liquid was
culture was taken of 3 to 4 hours to create a growth curve (A, n = 2). Representative
blot of Flag-tagged PR50 levels (B, n = 2).
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Figure 45. Overexpression of PR50 is associated with increased H3S10ph levels. A
summary of the histone PTMs surveyed in this study (A). Significant changes are
highlighted in red. Representative Western blot displaying H3S10ph levels and a
histogram compiling multiple biological replicates are shown alongside (B, n = 5). Error
bars represent +SD. ** = p < 0.01.
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Figure 46. The rise H3S10ph levels correlates with the expression of PR50. Spotting
assays depict cell viability in glucose, sucrose, galactose and various ratios of sucrose
and galactose (A, n = 3). Representative Western blots showing the expression of PR50
(B, n = 3). Representative Western blot displaying H3S10ph levels and a histogram
compiling multiple biological replicates are shown alongside (C, n = 4). Error bars
represent +SD. * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
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Figure 47. H3S10ph levels are significantly raised in various C9 ALS in vitro
models. Representative Western blots showing H3S10ph levels in isolated histones
from age matched iPSCs (A, n = 5), isogenic iPSCs (B, n =5) and fibroblast (n = 3).
Histograms compiling multiple biological replicates are shown alongside blots. Error
bars represent +SD. * = p > 0.05, *** = p = 0.001.
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Figure 48. Aurora B Kinase is significantly enriched in the nuclear fraction of C9
Fibroblasts. Representative Western blot of Aurora B Kinase levels from the nuclear
fraction of a C9 fibroblasts line and age matched control. Histogram compiling multiple
biological replicates are shown alongside blot. Error bars represent +SD. ** = p > 0.01.
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Figure 49. Knockdown of Ipl1 rescues the growth suppression phenotype in PR50
yeast. Yeast integrated with a gene encoded FUS or an empty vector in a parental and
Ipl1 DAmP background were serially diluted 5-fold and spotted on glucose (off) or
galactose (on) medium (A, n = 3). Representative Western blots showing the expression
of PR50 (B, n = 3).
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Figure 50. Ipl1 knockdown restore H3S10ph levels in PR50 yeast. Representative
Western blot displaying H3S10ph levels in Ipl1 DAmP (A, n = 5) and parental strains (B
n = 5). Histograms compiling multiple biological replicates are shown alongside. Error
bars represent +SD. Representative. * = p < 0.05.
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